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A large body of literature suggests that amyotrophic lateral sclerosis (ALS) pathology
is intimately linked with both aggregated proteins and neuroinflammation; specifically
activation, recruitment and dysfunction of microglia and astrocytes. However, there
has been little work performed that aimed to understand the impact that aggregates of
Cu/Zn superoxide dismutase (SOD1) have on microglia and/or astrocytes.

Mutant SOD1 associated with ALS has recently been shown to activate microglia in a
CD14 dependant mechanism when found in the extracellular space, providing one
potential explanation of glial activation during disease. Recent work demonstrates a
strong link between protein inclusions and cell loss and as a result neuroinflammation
in ALS and although they may be made up of different proteins, inclusions are
associated with all forms of ALS. With this in mind, the first aim of this project sought
to determine if aggregated SOD1 would activate microglia. Recombinant SOD1 was
aggregated and this, or soluble non-aggregated forms of SOD1 were then added to
EOC.13 microglial cells or primary microglial cells in culture. Although soluble nonaggregated mutant SOD1 has been shown to promote microglial activation in the past,
we found that aggregated SOD1 was able to much more efficiently activate microglia
in culture when compared with the unaggregated form of mutant SOD1. In addition to
CD14 dependant pathways, aggregated SOD1 also bound to the surface of glial cells
and was internalized in a lipid raft and scavenger receptor dependent manner. Here,
for the first time, we have shown that aggregated mutant SOD1 potently activates
microglia.

There is growing evidence to suggest astrocyte dysfunction in ALS. Previous evidence
has suggested that accumulation of mutant Cu/Zn superoxide dismutase (SOD1)
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initiates activation of ER stress in motor neurons. As protein inclusions have been
observed in astrocytes in ALS, the second aim of this project sought to determine if
exogenous aggregated mutant SOD1 would affect activation or viability of primary
astrocytes. Recombinant mutant SOD1 was aggregated and subsequently added to
primary astrocytes in culture. Exogenously added aggregated mutant SOD1 was taken
up into the cytosol of astrocytes, remained there for at least 7 days, causing
endoplasmic reticulum stress, astrocyte senescence and ultimately cell death. With
the use of a panel of endocytosis inhibitors we were able to show that aggregated
SOD1 was internalized by primary astrocytes via macropinocytosis. This work, for the
first time, links uptake of aggregated mutant SOD1 to dysfunction and toxicity in
primary astrocytes.

While the first two chapters showed dramatic effects this was performed in 2 D
cultures. To demonstrate glial dysfunction in a biological system proteins were infused
or injected in to the nervous system of mice. Here we report that soluble SOD1G93A
infused over 5 weeks into the brains ventricles of wild type mice, resulted in no
significant impact on anterior horn microglia and astrocytes, when compared to soluble
SOD1WT infusion. Whereas, 72 hours after injection aggregated SOD1 caused
increased microglial activity and caused astrocyte senescence around murine brain
ventricles. These results suggest that the aggregated form of SOD1 has a significant
impact on the activation state of microglia and astrocyte dysfunction in vivo, and may
directly affect disease progression in ALS. As a result, future therapeutics that work
simultaneously to prevent SOD1 aggregate induced microglial activation and astrocyte
dysfunction may be effective in slowing ALS progression.
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1.1 Prevalence and types of ALS
Amyotrophic Lateral Sclerosis (ALS) is a lethal, rapidly progressive neurodegenerative disease, which generally develops in patients between 50 and 60 years
of age. Estimates suggest that 3-7 people per 100,000 suffer from ALS (Benatar et al.
2006), and in Australia alone approximately 400 people die of ALS each year (Kiernan
et al. 2006). ALS is commonly referred to as Motor Neuron Disease (MND) in Australia
and the UK but is only one of several motor neuron diseases. ALS involves the
degeneration of both the upper and lower motor neurons in the spinal cord, cortex and
brain stem, while other motor neuron diseases (such as primary lateral sclerosis,
progressive muscular atrophy, progressive bulbar palsy and pseudobulbar palsy)
attack only upper or lower motor neurons (Wohlfart et al. 1955, Steele et al. 1964,
Pringle et al. 1992, Karam et al. 2010).

The French neurobiologist Jean-Martin Charcot first described the clinical features of
ALS almost 140 years ago but the molecular basis of ALS is still not clear.
Approximately 90-95% of cases are sporadic (not inherited) and still very little is known
about the cause of sporadic disease. However, recently TAR DNA binding protein
43kDa (TDP-43) has been identified as a major component of pathological protein
deposits associated with sporadic cases of ALS (Arai et al. 2006). Although familial
forms of ALS are less common, with about 5-10% of cases of ALS being inherited from
generation to generation (Benatar et al. 2006), they are the most well studied. Since
the clinical and pathological profiles are very similar, insights into familial ALS should
provide insight into sporadic ALS (Pasinelli and Brown 2006). There are over ten
genes with mutations that have been found to be associated with ALS (Table 1.1).
Hexanucleotide repeats in the gene C9ORF2 has been found to be the most common
23 | P a g e

cause of ALS (reviewed in (Ince et al. 2011). Mutations in the Superoxide dismutase
1 (SOD1) gene remains one of the most common causes of ALS and its protein
products appearance in protein aggregates is well established. Regardless of cellular
function, one hallmark links all forms of sporadic and familial forms of ALS, the
appearance of protein aggregates in inclusions in affected tissue.
Table 1.1: Genes and their functions with one or more known mutation which is
associated with ALS
Genes with mutations known to
be associated with ALS
Superoxide dismutase 1 (SOD1)
(Rosen et al. 1993)
C9ORF72
(DeJesus-Hernandez et al. 2011)
TAR DNA binding protein (TARDBP) TDP-43 (Arai et al.
2006)
Fused in sarcoma (FUS)
(Kwiatkowski et al. 2009)
Angiogenin (ANG)
(Greenway et al. 2004)
Optineurin (OPTN)
(Maruyama et al. 2010)
Ubiquilin 2 (UBQLN2)
(Deng et al. 2011)
Sigma nonopioid intracellular receptor 1 (SIGMAR1)
(Al-Saif et al. 2011)

Function of Genes/Proteins
Superoxide-scavenging enzyme
Yet unknown function
Represses transcription
Transcriptional activation
Stimulates new blood vessel formation
May be involved in Transcriptional activation
Regulates the degradation of ubiquitinated
proteins
Thought to be involve in lipid transport

Senataxin (SETX)
(Chen et al. 2004)

Thought to be involve in DNA repair

Alsin (ALS2)
(Yang et al. 2001)

May play a role in the development of axons
and dendrites

Vesicle associated membrane protein (VAPB)
(Nishimura et al. 2004)
Vasolin-containing protein (VCP)
(Ishigaki et al. 2004)
D-Amino acid oxidase (DAO)
(Mitchell et al. 2010)
Dynactin subunit 1(DCTN1)
(Munch et al. 2004)
Phosphoinositide 5-phosphatase (FIG4)
(Chow et al. 2009)
Ataxin 2 (ATXN2)
(Elden et al. 2010)
Neurofilament, heavy polypeptide (NEFH)
(Figlewicz et al. 1994)
Peripherin (PRPH)
(Leung et al. 2004)
Survival motor neuron, telomeric (SMN1)
(Veldink et al. 2001)
Spastic paraplegia 11 (SPG11)
(Daoud et al. 2012)

Thought to be involved in vesicle tracking
Assembly of peroxisomes, 26S proteasome
function, vesicle transport and fusion
May be important in removal of D-amino acids
Cell division and transport within the cell
Thought to be important in vesicle tracking
May be involved in RNA processing
Makes a protein component of neurofilaments
Formation of intermediate filaments
Important in supporting motor neurons
May play a role in gene expression or protein
trafficking
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1.2. Protein aggregation
When abnormally folded proteins cannot be degraded or refolded they are prone to
aggregation and can form structured, highly organized amyloid fibrils (Serpell et al.
2000) or unstructured, disorganized amorphous aggregates (Dobson 2004). Recent
research suggest that the prefibrillar forms of amyloid fibrils may be the most toxic (for
an in depth review see (Baglioni et al. 2006)); however, all aggregates are likely to be
detrimental, although, the exact mechanisms of toxicity are not fully understood. One
proposed mechanism for oligomer toxicity is that exposed hydrophobic residues
interact with cell receptors and membranes (Stefani and Dobson 2003, Cecchi et al.
2005, Bolognesi et al. 2010, Campioni et al. 2010), while a possible explanation for
inclusion toxicity is the sequestration of vital cellular components such as molecular
chaperones (Yerbury et al. 2016).

Amyloid fibrils are a key pathological feature of many diseases and this has led to a
need to characterize their formation (Chiti and Dobson 2006). In vitro imaging of
amyloid fibrils, using transmission electron microscopy and atomic force microscopy
has demonstrated that fibrils consist of 2 to 6 protofilaments, that are 60-120 Å in
diameter and of indeterminate length (Serpell et al. 2000). X-ray fiber diffraction has
revealed that the ordered structure of fibrils is comprised of E-strands that are
perpendicular to the fibrils axis giving it a twisted appearance (Sunde and Blake 1997).
Studies involving thioflavin T binding of E-strands have shown that the conversion of
proteins into amyloid fibrils involves a lag phase (Naiki et al. 1997, Serio et al. 2000,
Pedersen et al. 2004). This is thought to be the time it takes for the nuclei to form; and
once the nuclei forms, fibril growth is believed to proceed rapidly during what is termed
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the elongation phase until formation reaches a plateau when mature amyloid fibrils are
formed (Chiti and Dobson 2006, Wilson et al. 2008). There are also now reported
fibrillar aggregates that are not amyloid. SOD1 fibrils might not have a classical
amyloid structure and FUS and TDP-43 form fibrils have been called hydrogels or in
phase transition (Saini and Chauhan 2014, Patel et al. 2015).

Because the amino acid sequence determines the conformation of a protein, certain
changes in the amino acid sequence (through mutation) may result in a change in
what is known as the protein folding landscape (Chiti et al. 2002, Gregersen et al.
2006). The protein folding landscape represents how proteins attempt to reach their
native state (or functional state) assuming this state is the one with the lowest amount
of free energy (Gregersen et al. 2006). The folding funnel can be altered to include
two valleys, where mutations in the sequence lead to another pathway that has a free
energy minimum lower than that of the native protein (Clark 2004, Gregersen et al.
2006). Clark’s (2004) incorporation of a funnel for the probability of aggregation
reflects more accurately the frequent failure of proteins to fold correctly. Changes to
the amino acid sequence through the mutation of key residues are thought to increase
the chance of protein aggregation that decrease net charge, increase hydrophobic
residues and thought to increase the propensity to form E-sheets (Chiti and Dobson
2006). Failure of proteins to reach their native structure is also thought to be
detrimental and cause disease due to a loss of function of the misfolded protein and
inhibition of normal cell function (Hartl et al. 2011).
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1.2.1 Protein quality control
Because correct protein folding is required for proper protein function and thus cell
viability, it is not surprising that quality control systems have evolved to inhibit protein
misfolding and aggregation (Yerbury et al. 2005). Protein homeostasis (proteostasis),
describes the concept of the maintenance of the correct folding, unfolding, trafficking,
and turnover of the entire proteome which is important to maintain healthy cellular
function (Balch et al. 2008). Protein unfolding occurs when the correct protein
conformation is obtained but conditions in the cell are unfavorable and result in folded
proteins unraveling (Stefani and Dobson 2003). Unfavorable conditions, such as
higher temperature, acidic pH and moderate concentrations of salts, promote
unfolding by destabilizing bonds in the native structure (Stefani and Dobson 2003).
Protein misfolding on the other hand refers to proteins that may never reach their
native conformation and thus cannot perform their normal functions. Chaperones are
a major part of the quality control system whose role it is to prevent aggregation and
promote efficient protein folding (Hartl et al. 2011). Many heat shock proteins (HSP)
are chaperones and are divided into classes based on their approximate molecular
mass in kDa. In the cytosol for example, one of the many jobs of HSP70 is its
association with polypeptide chains as proteins are being synthesized from the
ribosome and thus it assists with folding by energy dependent binding and release
(Taylor et al. 2002). Other cytosolic chaperones are sometimes needed for further
folding such as HSP90 and HSP60 (with HSP60 more commonly known as a
chaperonin) before a protein can reach its native conformation (Hartl and Hayer-Hartl
2002, Hartl et al. 2011). A proportion of all proteins tend not to fold correctly or may
unfold as a result of stress. Chaperones, such as the small HSP (sHSP), may bind
these misfolded or unfolded proteins in an ATP independent fashion permitting
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refolding by other chaperones, or alternatively unfolding for another chance to be
correctly folded or eventually degraded (McClellan et al. 2005).

One of the major mechanisms through which cells achieve selective protein
degradation is the ubiquitin proteasome system (Schubert et al. 2000). Proteins that
are no longer required or proteins that are unable to fold correctly are “tagged” by
covalent ligation to ubiquitin (through a multistep pathway involving the formation of a
aggresome) and are degraded by the 26S proteasome complex in a process known
as aggrephagy (Hershko and Ciechanover 1998). Another pathway that can be
employed to degrade aggregated proteins is the lysosome system. Chaperone
mediated autophagy, and macroautophagy are both involved in shuttling misfolded
proteins and aggregates for degradation via acidic proteases in the lysosome (Cuervo
2010, Filimonenko et al. 2010). While degradation via the ubiquitin proteasome
system requires the misfolded protein to be small enough to enter the narrow pore of
the proteasome, larger aggregates can be degraded by macroautophagy
(Knaevelsrud and Simonsen 2010).

1.2.2 Aggregation and its role in ALS
Inclusions containing protein aggregates are a characteristic pathological feature
occurring in all forms of human ALS. In humans and transgenic mice with SOD1
related ALS, aggregates of mutant SOD1 have been found in motor neurons and in
astrocytes (examples can be seen in Figure 1.1) (Bruijn et al. 1998). It is unclear if
SOD1 aggregates are toxic, but their presence is associated with cell death (Bruijn et
al. 1998). It is thought that aggregates of SOD1 cause ER stress, protein transport
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blockage, inhibition of organelle function, inhibition of proteasome machinery, and
decreased chaperone activity which may in turn result in cell death (Bruijn et al. 2004).

A

B

C

Figure 1.1: Neuropathology of ALS. Aggregates found in the spinal cord tissue from
patients with a SOD1 mutation A) Inclusions in a spinal motor neuron, B) Inclusions in
astrocytes, misSOD1 (green) and the astrocyte marker GFAP (red), C) Aggregates in
microglia, misSOD1 (green) and the microglial marker Iba1 (red) (Saberi et al. 2015,
Forsberg et al. 2011).
Impaired protein degradation due to the proteasome becoming overwhelmed with
excessive amounts of misfolded and aggregated mutant protein in later life is a
promising theory of aggregation induced toxicity (Kastle and Grune 2011). It has been
shown that mutant SOD1 inhibits the proteasome (Urushitani et al. 2002), with
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inhibition thought to be caused by the proteasome becoming “choked” with mutant
SOD1 (Cleveland and Rothstein 2001, Urushitani et al. 2002). The impairment of
protein degradation would not only affect mutant SOD1, but all other proteins that the
proteasome processes in order to achieve normal proteostasis (Pasinelli and Brown
2006). Antibodies to ubiquitin have been found to be immunoreactive to inclusions in
all mutant SOD1 mouse models and ALS patients (Bruijn et al. 2004).

Chaperones responsible for correct protein folding, and anti-apoptotic proteins such
as B cell lymphoma 2 (Pasinelli et al. 2004), are also found associated with protein
aggregates, and this may inhibit correct cell functioning (Pasinelli and Brown 2006).
Certain chaperones, such as DE-crystallin, HSP27, HSP40 and HSP70, have been
found to interact with mutant SOD1 (Shinder et al. 2001). HSP70 has been found to
interact “transiently” with the mutant SOD1 aggregates and seems not be sequestered
in aggregates (Matsumoto et al. 2005). Whereas DE-crystallin has been shown to be
sequestered by the insoluble mutant SOD1 aggregates in mutant SOD1 mice (Wang
et al. 2008). With at least a subset of chaperones sequestered into protein aggregates
of mutant SOD1, chaperone assisted protein quality control of all proteins is likely to
be impaired resulting in impaired proteostasis. The collapse of proteostasis could lead
to a multitude of cellular dysfunctions across various pathways reminiscent of the
disparate cellular functions reported to be involved in SOD1 mediated cell death
(Cleveland and Rothstein 2001). This disruption of normal cellular function may
explain why mutant SOD1 is toxic to motor neurons, but it does not explain why motor
neuron degeneration is not randomly scattered throughout the CNS but is instead
seemingly spread from motor neuron to motor neuron (Shaw 2002).

30 | P a g e

1.3. SOD1
Copper/zinc superoxide dismutase (SOD1) is a superoxide-scavenging enzyme that
is found in the cytosol. SOD1 is a homo-dimer consisting of two polypeptides of 153
amino acids, with each subunit containing one copper and one zinc atom (Cleveland
and Rothstein 2001). It was previously known as erythrocuprein (Markowitz et al.
1959) and until 1969 its function was unknown. It was found to have a molecular weight
of 34,000, to contain 0.34% copper and it was shown to have an enzymatic function,
with experiments showing that it catalyzes the dismutation of superoxide free radicals
(McCord and Fridovic.I 1969). Superoxide free radicals are a by-product of oxidative
phosphorylation in the mitochondrion (Pasinelli and Brown 2006). The free radical
superoxide needs to be rapidly converted into less reactive molecules because it
causes tissue damage by reacting with sulfhydryl bonds, cell membranes and the
nucleotides in DNA (Machlin and Bendich 1987). In addition, superoxide can react with
nitric oxide (NO-) to produce the dangerous peroxynitrite (Pryor and Squadrito 1995).
The copper atom is key to the process of dismutation of superoxide, being reduced
and oxidized to produce O2 and 2H2O2 (Cleveland and Rothstein 2001).

1.3.1 Mutations in SOD1 and its implications
Mutations in the SOD1 gene account for approximately 20% of familial cases of ALS
(Benatar et al. 2006). At first it was thought that a mutation in the SOD1 gene caused
a decrease in enzyme activity and that this resulted in an increase in reactive oxygen
species, which subsequently induced damage to motor neurons (Bowling et al. 1993,
Deng et al. 1993). However, in vitro studies showed that different SOD1 mutants had
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varying levels of enzymatic activity that did not relate to the rate of progression or to
the age of onset of disease (Cleveland et al. 1995). Indeed it was found some mutants
that have full enzymatic activity, still cause ALS (Borchelt et al. 1994). Further,
increasing the levels of wild type SOD1 and hence the dismutase activity did not slow
disease progression (Bruijn et al. 1998). In fact, in one study increasing the wild type
SOD1 concentration was shown to accelerate disease in mice (Jaarsma et al. 2008).
Transgenic mice over expressing mutant human SOD1 have been shown to develop
ALS (Gurney et al. 1994) while mice with a deletion of the SOD1 did not develop
symptoms typical of ALS (Reaume et al. 1996). This suggests that mutant SOD1
causes disease through a toxic gain in function. This is consistent with other diseases
such as Parkinson’s disease, keratin and collagen diseases which are inherited
dominantly and are caused by a toxic gain in function (Gregersen et al. 2006).

Over 100 different mutations of the SOD1 gene associated with ALS have been
identified (Pasinelli and Brown 2006). It is thought that all of these mutations are able
to destabilize the structure of the SOD1 protein (Borchelt et al. 1994). These various
mutations do not occur at one common location (for example, at the active site),
instead they have been identified throughout the entire structure (Valentine et al.
2005). It is now commonly acknowledged that mutations in the SOD1 gene are
associated with a propensity to misfold and aggregate. However, how misfolded or
aggregated SOD1 causes ALS is not fully understood. Nevertheless, it is currently
acknowledged that 30% of small interneurons also degenerate in ALS (Cleveland and
Rothstein 2001) and that protein inclusions and neuro-inflammation are important
features which occur concurrently during the course of disease.
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1.4. Neuroinflammation
Neuroinflammation allows the body to rapidly recruit pathogen fighting molecules and
cells to the site of insult in the central nervous system (CNS). Acute inflammation in
the CNS caused by infections, trauma, stroke and toxins is considered beneficial, as
it stops further injury, repairs damage and is short lived. Chronic inflammation in the
CNS occurs over an extended period of time, longer than normally would be
necessary. Instead of quickly clearing the area of harmful pathogens the prolonged
inflammation can be harmful to surrounding healthy tissue and cells; by releasing
reactive oxygen species, nitric oxide, tumour necrosis factor alpha (TNF-α), breaking
down the blood brain barrier and recruiting immune cells from the periphery when the
blood brain barrier is compromised. This is thought to contribute to the progression of
many neurodegenerative diseases where neuroinflammation is associated (Hook et
al. 2015).

It is necessary for the immune system in the CNS (and for that matter in the periphery)
to differentiate between foreign or abnormal cells/molecules and normal healthy cells
and their products (Wyss-Coray and Mucke 2002). In the periphery, acquired immunity
requires the production of lymphocytes (T cells and B cells) and immunoglobulins to
recognize and remember threats. Natural killer cells, macrophages, neutrophils,
dendritic cells, basophils and eosinophils are the major cells which contribute to innate
immunity in the periphery. However, in the CNS the resident innate immune cells are
astrocytes and microglia. Microglia and astrocytes are important in producing many
cytokines and many of the components in the complement system of the CNS
(McGeer and McGeer 1995).
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1.4.1 Evidence of increased expression of neuroinflammatory markers in ALS
There is increasing evidence that inflammation is a major part of ALS pathology. The
increased expression of a number of neuroinflammatory markers strongly suggests
this is the case. One of these is cyclooxygenase-2 is a pro-inflammatory enzyme which
converts arachidonic acid to prostaglandin and is produced in multiple cell types
including astrocytes and neurons (McGeer and McGeer 2002). Cyclooxygenase-2
expression can be induced by a number of factors including TNF-α, IL-1β, LPS,
elevated calcium levels and multiple growth factors (Consilvio et al. 2004). It has been
found to be upregulated in both transgenic mutant SOD1 mouse models and patients
with ALS (Almer et al. 2001). It is important in synthesis of Prostaglandin E2 which has
been found at levels 2 to 10 times higher in greater than 80% of ALS patients examined
compared to the control group (Almer et al. 2002). Prostaglandin E2 induces the
release of glutamate from astrocytes and this increase in glutamate has been
implicated in contributing to motor neuron loss in ALS (Consilvio et al. 2004, Dave et
al. 2010).

Inducible nitric oxide synthase is used by microglia to produce nitric oxide (NO) to
protect against various insults to the host. Nitric oxide can be beneficial when there is
a bacterial infection as it can inhibit bacterial DNA synthesis, cause double stranded
breaks, interact with metal groups in the bacterial enzymes and oxidize bacterial lipids
(Lowenstein and Padalko 2004). However, excessive nitric oxide production, as
occurs when there is chronic neuroinflammation, is thought to be neurotoxic and has
been implicated in a number of neurodegenerative diseases (Liu et al. 2002).
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Postmortem spinal cord tissue of 15 patients with ALS, showed increased iNOS
immunoreactivity in both astrocytes and neurons when compared to control patients
(Sasaki et al. 2000). Indicating increased oxidative damage in the motor system may
contribute to neuronal degeneration in ALS (Sasaki et al. 2000).

Interleukin-6 (IL-6), also known as B-cell stimulating factor, is a proinflammatory
cytokine in the CNS, predominantly produced by astrocytes and microglia (Sekizawa
et al. 1998). Increased levels of IL-6 have been found in the CSF of patients with HIV1,
bacterial meningitis and viral encephalitis (Platasalaman 1991). Transgenic mice over
expressing IL-6 in the CNS were shown to develop motor impairment and suffer from
seizures (Campbell et al. 1993). This transgenic mouse model with increased levels
of IL-6 showed increased levels of complement proteins, angiogenesis and breakdown
of the blood brain barrier (Campbell et al. 1993). Research also shows that IL-6 may
influence inflammation by triggering the differentiation of monocytes to macrophages
rather than dendritic cells (Chomarat et al. 2000). This together with evidence of
increased levels of IL-6 in neurodegenerative disease suggests that IL-6 may play a
role in progression of neurological diseases where increased levels are found.
Elevated levels of IL-6 have been found in ALS patients compared to patients with
multiple sclerosis or HTLV-1 associated myelopathy (Sekizawa et al. 1998). Recent
research shows that proinflammatory cytokines IL-12, IL-15, IL-17 and IL-23 are also
elevated in the CSF and serum of patients with ALS (Rentzos et al. 2010a, Rentzos
et al. 2010b).
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Monocyte chemoattractant protein 1 (MCP-1), also known as chemokine ligand 2
(CCL2), is important in recruiting monocytes, T-cells and dendritic cells to site of
inflammation in the CNS. As well as recruitment there is strong evidence to suggest
that MCP-1 also plays a role in permeabilisation of the BBB (Stamatovic et al. 2005).
An increase of MCP-1 is seen in post mortem tissue and the CSF of patients with ALS
(Henkel et al. 2004, Baron et al. 2005, Nagata et al. 2007, Gupta et al. 2011). This
data suggests that inflammatory cells are being recruited to damaged areas both from
within the CNS and potentially being recruited from the peripheral system.

Tumor necrosis factor alpha (TNF-α) is a proinflammatory cytokine and in the
periphery, TNF-α is produced by monocytes and macrophages (Barbara et al. 1996).
Originally, it was found to be an important component of the immune response in the
periphery, activated against tumor’s (hence the name). However, in the CNS microglia,
astrocytes and neurons are all responsible for the production of TNF-α in response to
stimuli (Cristina et al. 2012). In the diseased brain an increased level of TNF-α can
have a neurotoxic effect. It is found to be elevated in a number of neurodegenerative
diseases including Parkinson’s disease, multiple sclerosis and Alzheimer’s disease
(Beck et al. 1988, Fillit et al. 1991, Boka et al. 1994). Significantly, higher levels of
TNF-α and its receptor sTNFR were found in plasma from patients with ALS compared
to controls (Poloni et al. 2000). A subsequent study also found increases in TNF-α and
two of its receptors in the plasma of patients with sporadic ALS (Cristina et al. 2012).
Interestingly this study found that the higher levels of TNF-α seen in the plasma of
patients with ALS is present at disease onset and remains throughout disease
progression (Cristina et al. 2012).
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Collectively, this data implicates inflammation as an integral part of ALS pathology.
The increase in neuroinflammatory markers is consistent with the idea that
neuroinflammation plays an important role at disease onset and contributes to
progression in ALS patients.

1.4.2. Evidence of increased expression of neuroinflammatory markers in
transgenic mutant SOD1 mice
After the initial finding of mutations in the SOD1 gene (Rosen et al. 1993), transgenic
mutant SOD1 mice were produced expressing human mutant SOD1 (Gurney et al.
1994). Similar to humans, transgenic mutant SOD1 mice show evidence of protein
aggregates, motor neuron loss and neuroinflammation, making them a useful model
to utilise when studying ALS (Turner and Talbot 2008).

Studies in transgenic mutant SOD1 mice have shown that increased expression of
inducible nitric oxide synthase corresponded with disease progression (Almer et al.
1999). Nitric oxide synthase (iNos) was increased in glial cells in pre-symptomatic and
end stage mutant SOD1 mice (Almer et al. 1999). SOD1G93A mice have been shown
to have higher levels of NOX2 (an isoform of nicotinamide adenine dinucleotide
phosphate (NADPH) -oxidase) and superoxide in spinal cord microglia when
compared to spinal cord tissue from wild type mice (Wu et al. 2006). NADPH oxidases
which include NOX1 and NOX2 generate superoxide by transferring electrons from
NADPH to molecular oxygen. Superoxide which can be produced by microglia (see
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below) is harmful to neurons (Saez et al. 1987). NOX2 null crossed with mutant SOD1
mice had an extended lifespan compared to mutant SOD1 mice without the NOX2
knockout (Wu et al. 2006, Marden et al. 2007). However, in the Marden (Marden et al.
2007) study NOX2 knockout mice with the SOD1 mutation, were predisposed to lethal
eye infections. This potentially suggests that NOX2 is too important to the immune
system to be targeted for complete knockout in ALS.

Insulin growth factor 1(IGF-1) is a neuroprotective factor for motor neurons and it has
been shown to extend lifespan in mutant SOD1 mice (Kaspar et al. 2003). IGF-1
delayed astrogliosis, decreased TNF-α release by 59% and extended lifespan (by nine
days) in IGF-1 treated mutant SOD1 mice (Kaspar et al. 2003). However, clinical trials
involving subcutaneous delivery to patients with ALS unfortunately did not prove
beneficial to patients (Sorenson et al. 2008). In fact, IGF-1 gene expression was
shown to be up-regulated in leukocytes and microglia in mutant SOD1 mice spinal
cord (Chiu et al. 2013). With microglia taken from transgenic mice having significantly
higher levels of IGF-1 gene expression in all stages of disease (end stage,
symptomatic and pre-symptomatic mice) (Chiu et al. 2008). This, along with the failed
clinical studies in humans, suggests that although IGF is upregulated by microglia it
cannot adequately protect motor neurons in ALS patients or may contribute to motor
neuron loss through an unknown mechanism. Of note reduced IGF-1signaling was
shown to protect mice from behavioural impairments associated with the Aβ
aggregates in Alzheimer’s disease suggesting the role of IGF-1 in neurodegenerative
disease is complex (Cohen et al. 2009).

The early, relatively slow phase of disease progression is eliminated in the absence
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of functional CD4+ T cells, accompanied by increased proinflammatory and cytotoxic
factors, decreased anti-inflammatory and neurotrophic factors, and decreased survival
(Beers et al. 2008). In this same study when mutant SOD1 mice lacking CD4+ T cells
had bone transplants from wild type mice, there was a decrease in cytotoxic factors
TNF-α, NOX2 and IL-6, and an increase neuroprotection factors including IGF-1, IL-4
and Ym1 (Beers et al. 2008). The immunomodulatory effects of the CD4+
neuroprotective T cells appear to enhance a neuroprotective microglial phenotype with
increased anti-inflammatory factors and neurotrophic factors.

Transgenic mutant SOD1 T-cell-deficient (Tcr3-/-) mice, have confirmed that T cells
play an endogenous neuroprotective role in ALS (Chiu et al. 2008). Reconstitution of
mutant SOD1 mice with ex vivo expanded T regulatory or T effector cells from WT
donor mice delays the loss of motor function and enhances survival (Banerjee et al.
2008). An increased lymphocyte population was present at 65 days when compared
to non-transgenic mice (Chiu et al. 2008). As disease progressed in the transgenic
mice further increases in lymphocytes were seen at day 100 and day 135 (Chiu et al.
2008).

Increases in the levels of mRNA expression of IL-1β a proinflammatory cytokine, IL10 an anti-inflammatory cytokine and IL-6, which can act as both a proinflammatory
and anti-inflammatory cytokine have been observed in mutant SOD1 mice (Sekizawa
et al. 1998, Nguyen et al. 2001, Hensley et al. 2002). However, data from IL-1β
knockout in mutant SOD1 mice demonstrated that the proinflammatory interleukin-1β

39 | P a g e

was not solely required for ALS disease progression but may modulate the immune
response (Nguyen et al. 2001).

A significant increase in TNF-α concentration was observed in the spinal cord of
SOD1G93A mice compared to wild type mice (Hensley et al. 2003). In addition, when
stimulated with LPS, microglia from SOD1G93A mice have been shown to secrete more
inflammatory mediators, including TNF-α than control mice (Weydt et al. 2004).
Increases in TNF-α can be seen prior to symptom onset in SOD1G93A mice, indicating
that it may play a role at disease onset and not just at the end stages of disease
(Hensley et al. 2003).

1.5. The role of microglia in innate immunity and inflammation
Microglia are a component of the innate immune system and are considered to be the
macrophages of the CNS. In the healthy CNS, microglia are sometimes called
“inactive”, however this label is inaccurate as microglia are constantly using their
processes to sample and monitor the extracellular space (Davalos et al. 2005,
Nimmerjahn et al. 2005). When the brain is injured or affected by disease, the “less
active microglia” in the damaged area undergo rapid activation, which is characterized
by cell body enlargement, retracted processes, antigen presentation and
phagocytosis, production and secretion of neurotoxic compounds such as; reactive
oxygen species (ROS), growth factors and cytokines (Henkel et al. 2009). In addition,
they can be neuroprotective through release of neurotrophic factors (NTF), insulin
growth like factor-1 (IGF-1) and anti-inflammatory cytokines (Henkel et al. 2009).
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Like macrophages found in circulation (Taylor et al. 2002, Benoit et al. 2008, Henkel
et al. 2009), microglia have a spectrum of phenotypic states with the extremes being
the M1 and M2 phenotypes (Ponomarev et al. 2007, Michelucci et al. 2009). The M1
phenotype, known as classically activated microglia, are activated by proinflammatory
cytokines such as interferon gamma (IFN-J) and by lipopolysaccharides (LPS) on
microbes (Michelucci et al. 2009). The classically activated M1 microglia can be
neurotoxic because these microglia release reactive oxygen species (ROS),
proinflammatory cytokines (TNF-α, IL-1), and reduce trophic factors (Figure 1.2a)
(Henkel et al. 2009, Michelucci et al. 2009). The M2 phenotype on the other hand is
considered more neuroprotective because it reduces inflammation by blocking the
release of proinflammatory cytokines and mopping up endocytic factors after
inflammation occurs (Henkel et al. 2009)(Figure 1.2b).
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Figure 1.2: Representations of the M1 and M2 microglial phenotypes neurotoxic
and neuroprotective effect on motor neurons. a) Neurotoxic M1 microglia release
reactive oxygen species (NO, O2-), proinflammatory cytokines (TNF-D, IL-1E, IL-6, IL12, IL-23) directly or indirectly causing motor neuron stress and death. b)
Neuroprotective M2 microglia release neurotrophic (NTF) and growth factors (such as
IGF-1).

1.6. Astrocytes role in the CNS
Astrocytes and oligodendrocytes are the macroglia of the central nervous system.
Astrocytes are an important part of the CNS providing metabolic, structural and trophic
support to surrounding neurons (Bezzi and Volterra 2001). In healthy human
physiology, they maintain homeostasis in the CNS via the uptake and release of ions
and neurotransmitters from the extracellular fluid surrounding neurons (Figure 1.3)
(Sofroniew and Vinters 2010). Astrocytes also play a critical role in maintenance of the
BBB by releasing soluble factors such as basic fibroblast growth factor, glial derived
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neurotrophic factor (NTF) and transforming growth factor beta (TGF-β). The release
of various neurotrophic factors from astrocytes (such as nerve growth factor, ciliary
neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth
factor, and insulin growth factor) supports; oligodendrocyte survival, remyelination,
neurogenesis and neuronal survival differentiation, function and regeneration (Farina
et al. 2007). Astrocytes, also release chemokines and cytokines that are important in
myelination (IL-1 and IL-6) and in neural progenitors (CCL2 and CXCL12) (for in depth
review (Farina et al. 2007).

Astrocytes can also play a role in immunity in the central nervous system. When
astrocytes encounter a foreign stimulus (Figure 1.3; for in depth review (Benveniste
1998) they can be activated, through a process known as astrogliosis, where they
undergo significant morphological changes and proliferation. Like microglia (as
mentioned previously) astrocytes can be either pro- or anti-inflammatory (Sofroniew
and Vinters 2010), and there exists a spectrum of astrogliosis ranging from mild
reactive astrogliosis that can be quickly resolved to severe reactive astrogliosis which
can result in long lasting changes in the tissue architecture (Sofroniew and Vinters
2010). Reactive astrocytes can release cytokines (IL-6, MCP-1,TNF) and chemokines
(CCL2, CCL5,CXCL10 and CXCL12) which contribute to inflammation (Farina et al.
2007).

Astrocytes will also enhance the expression of glial fibrillary acidic protein (GFAP),
which is thought to be important in modulating shape, and is commonly used as an
astrocyte marker in scientific experiments (Eng et al. 2000, Dong and Benveniste
2001). However, some astrocytes in the normal healthy CNS do not express
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detectable levels of GFAP and so an increase in GFAP can used as a marker of
increased reactive astrocytes but not an increase in astrocyte population per se
(Sofroniew and Vinters 2010). After damage to the CNS they are essential in BBB
repair, and in severe cases can form scars to prevent the spread of infection
(Sofroniew and Vinters 2010). These glial scars can also prevent damaging
inflammatory cells from escaping the site of injury (Sofroniew and Vinters 2010).

Astrocytes can also cause motor neuron injury through non-immune mechanisms.
Astrocyte senescence is now thought to be a contributing factor in other neurological
diseases such as Alzheimer’s disease (Bhat et al. 2012). Rather than being simply a
loss of protective function, senescent cells are functionally altered. One of the most
important functions in the CNS is thought to be the maintenance of extracellular
glutamate levels. This is because, unlike acetylcholine, which is enzymatically
degraded at the neuromuscular junction, uptake and clearance of glutamate occurs
via glutamate transporter proteins in astrocytes. The over stimulation by excess
glutamate causes excitotoxicity in neurons due to overstimulation and an excess influx
of calcium ions (Arundine and Tymianski 2003). Abnormal levels of glutamate have
been found in cases of traumatic brain injury and a number neurodegenerative
conditions such as Parkinson’s disease, Alzheimer’s disease, multiple sclerosis and
ALS (Hyman et al. 1987, Baker et al. 1993, Srinivasan et al. 2005, Griffith et al. 2008).
Of interest the only drug widely recommended for use in ALS, Riluzole, is a modulator
of glutamate (discussed further in Chapter 7.2) (Miller et al. 2007).
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A) Typical
astrocytes

Figure 1.3: Astrocytes role in the central nervous system. Different phenotypes of
astrocytes and their effect of motor neurons; A) A representation of how astrocytes
affect motor neurons in the typical CNS, B) Astrocytes reaction during
neuroinflammation possibly resulting in motor neuron stress and death, C) Possible
astrocyte dysfunction in senescent astrocytes possibly resulting in motor neuron stress
and death.
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1.7. The role of non-neuronal cells in ALS
1.7.1 The role of microglia’s in ALS
Numerous studies have shown that microglia are activated and proliferate in ALS
patients and ALS mice models (Lampson et al. 1988, Kawamata et al. 1992, Henkel
et al. 2004, Turner et al. 2004, Moisse and Strong 2006). As the disease increases in
severity, the activation of microglia has also been shown to increase in vivo in ALS
patients (Turner et al. 2004). Microglial activation is seen in mutant SOD1 transgenic
mice before symptoms appear and throughout disease progression (Hall et al. 1998,
Alexianu et al. 2001, Clement et al. 2003). However, as mentioned previously
activation of microglia may be either a neuroprotective response or a neurotoxic
response. It is unclear whether activation of microglia in ALS is neuroprotective or
contributes to rapid disease progression (Henkel et al. 2009). It has recently been
suggested that neuroprotective M2 microglia may slow disease progression early
during the course of disease, but may be replaced by neurotoxic M1 microglia and
may contribute to disease progression at later stages of ALS (Henkel et al. 2009, Appel
et al. 2011).

Immunocytochemistry of postmortem tissue from ALS patients demonstrated
microglial activation and indicated that an immune response may play a role in motor
neuron death (Troost et al. 1993). However, this end stage work does not indicate
whether microglial activation occurred during the course of the disease or was evident
only at the end stage of disease. Positron emission tomography imaging of ALS
patients, using [11C](R)-PK11195 and [11C]-PBR28 (with both radiotracers shown to
bind specifically to activated microglia), showed an increase in activated microglia in
the motor cortex, that correlates with upper motor neuron symptoms seen in patients
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(Banati 2002, Turner et al. 2004, Zürcher et al. 2015). This observed correlation
supports previous mouse work which showed that microglial activation is not just an
end stage phenomenon and thus may contribute to disease progression in ALS.

Microglia are activated prior to symptom onset but it is still not certain whether they
play a neuroprotective or neurotoxic role (Henkel et al. 2006). Ablating microglial
expression of mutant SOD1 or transplanting bone marrow from wild-type mice into
mutant SOD1 transgenic mice increases the life span of mutant mice (Beers et al.
2006, Boillee et al. 2006). This suggests that microglia play a neurotoxic role during
disease progression. In addition, microglia that express mutant SOD1 are more readily
activated and induce more motor neuron cell death than WT microglia. Xiao et al
(2007) found that upon stimulation with lipopolysaccharide (LPS) mutant SOD1
microglia released more neurotoxic superoxide and nitric oxide when compared to wild
type microglia. Microglial cells from mutant SOD1 mice stimulated with LPS secrete
more inflammatory mediators, including TNF-α (Weydt et al. 2004), MCP-1, TGF-β
(Henkel et al. 2004) and IFN-γ (Ferri et al. 2004), than cells from control mice. When
using mixed cultures of motor neurons and microglia this resulted in SOD1G93A
expressing microglia causing greater motor neuron death (Xiao et al. 2007).

1.7.2 Astrocytes role in ALS
A significant increase in astrocytic activation is seen in mutant SOD1 mice upon
disease onset and throughout the early stages of disease progression (Hall et al.
1998). It has also been revealed that astrocytes from neonatal rat spinal cords,
become reactive after incubation with CSF from ALS patients (Shahani et al. 1998).
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Diminished mutant SOD1 expression in astrocytes did not affect disease onset but
delayed microglial activation and slowed disease progression (Yamanaka et al. 2008).
This suggests that astrocytes are important for disease progression and may interact
with microglia to cause damage to motor neurons in ALS.

There

is

growing

evidence

of

astrocyte

senescence

observed

in

other

neurodegenerative diseases including Parkinson’s and Alzheimer’s disease (Bhat et
al. 2012, Chinta et al. 2013). In a rat model of ALS an increase in β-galactosidase
staining in spinal cord sections was demonstrated suggesting that astrocyte
senescence may be deleterious in the mutant SOD1 rat model for ALS (Das and
Svendsen 2015). However, the cause of this astrocyte senescence remains unclear.

Although the underlying mechanism of astrocyte senescence and/or dysfunction in
ALS remains unknown, evidence that this dysfunction causes, the increased levels of
glutamate led to the only approved drug for patients with ALS (Bensimon et al. 1994).
Riluzole works by decreasing the levels glutamate, by blocking it’s presynaptic
release, which decreases the damage to motor neurons (Miller et al. 2007). However,
it only prolongs survival in patients with ALS for 2 to 3 months (Miller et al. 2007). Antiinflammatory drugs or immune modulating drugs have previously been trialled and
some clinical trials are currently underway (Table 1.2) (McGeer and McGeer 2002,
Traynor et al. 2006, Habib and Mitsumoto 2011).
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Table 1.2: Potential ALS therapeutics based on anti-inflammatory targets
(McGeer and McGeer 2002, Traynor et al. 2006, Habib and Mitsumoto 2011).
Drug to treat ALS

Proposed targets of drug

Ceftriaxone

Targets glutamate
transport in astrocytes
Targets neuronal
apoptosis, and microglia
and astrocyte activation
Targets neuronal
apoptosis, and microglia
and astrocyte activation
Free radical scavenger
may have antiinflammatory and
antiapoptotic effects.
Antiangiogenic and
immunomodulatory effects
Antiangiogenic and
immunomodulatory effects
Inhibitor of protein kinase
C
Antimicrobial agent and
inhibitor of microglia
COX-2 inhibitor

Pioglitazone
Rosiglitazone
Edaravone (MCI-186)

Thalidomide
Lenalidomide
Tamoxifen
Minocycline
Nimesulide (generic)
Celastrol

Suppresses TNF-α, IL-1β
and NO- production.

Outcomes and stages of
Development and testing
Phase ІІІ trials ongoing
Phase ІІ trials revealed no
benefit to patients
Negative cardiac
problems in patients
observed
Phase ІІІ trials (results not
yet released)
Caused Bradycardia in
50% of patients treated
Phase ІІ planed
Phase ІІ results promising
Phase ІІІ trials revealed
harmful effect to patients
Phase ІІІ trials revealed
no benefit to patients
Improved survival of
Mutant SOD1G93A mice

Reactive astrogliosis has been found in post mortem spinal cords of ALS patients
(Schiffer et al. 1996). This was at least an indication that astrogliosis is present at the
end stage of ALS disease. Examination of tissue prior to death was needed to see if
astrogliosis occurred prior to the end stage of disease progression. Deuteriumsubstituted [11C](L)-deprenyl was used to demonstrate astrogliosis in patients with
ALS (Johansson et al. 2007). Astrogliosis in patients with ALS is reasonably diffuse
occurring in the spinal cord, grey matter and subcortical matter of the brain (Kushner
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et al. 1990, Schiffer et al. 1996). A fairly recent study also indicated that astrocytes
that express mutant SOD1 will release factors (undetermined in this study) that are
selectively toxic to motor neurons (Nagai et al. 2007) and knock down of SOD1 in
astrocytes reduced the toxic effect on motor neurons (Haidet-Phillips et al. 2011).

1.7.3 Other cells that may contribute to dysfunction in ALS
Dendritic cells are antigen presenting cells and play a major role in modulating and
initiating the immune response (Banchereau and Steinman 1998). Dendritic cells can
exist as “immature” cells which are relatively inactive and unable to activate T cells
(Banchereau and Steinman 1998). As well as being activated by IL-1, TNF-α, CD40L, LPS, Bacteria, viruses and DNA, immature dendritic cells also respond to a large
number of chemokines such as chemokine ligand 3, chemokine ligand 4 and MCP-1
(Caux et al. 2000). In tissue and CSF from ALS patients an increased expression
MCP-1 has been observed (Henkel et al. 2004). Elevated immature and activated
dendritic cell transcripts were also found in ALS tissue samples this study (Henkel et
al. 2004). Interestingly, a correlation was found between an increased level of
expression of dendritic cell transcripts and a more rapid progression of ALS (Henkel
et al. 2004).

Natural killer (NK) cells are specialized lymphoid cells which can be activated to have
cytotoxic effects on abnormal cells (Biron et al. 1999). In particular they are known to
recognise some tumour cells and virally infected cells (Moretta and Moretta 2004).
When tumour or virally infected cells don’t have enough MHC I on their surface to be
recognised by other immune cells, NK cells can rapidly kill these abnormal cells
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(Moretta and Moretta 2004). NKT cells (which share markers with NK and T cells) have
been shown to increase in both the liver and the CNS of mutant SOD1 mice
(Finkelstein et al. 2011). This may suggest that peripheral immunity may also play a
role in disease progression.

T cells are normally found in the periphery (and not the CNS) where they regulate
other immune cells. Examination of the peripheral immune system indicate that during
advanced ALS disease, CD4+ T cell activation is significantly decreased compared to
control patients (Zhang et al. 2005). In one study, CD4+ T helper cells were found near
areas of degeneration in the cortical spinal tract an area responsible for motor neuron
signalling (Engelhardt et al. 1993). In this study, CD8+ T suppressor cytotoxic cells
were also observed in the ventral horns along with CD4+ T helper cells (Engelhardt et
al. 1993). More recent evidence has contradicted this, showing no evidence for CD4+
T-cell response, however they did detect CD8+ in post-mortem tissue suggesting a
neurotoxic role in the end stages of disease (Sta et al. 2011).

Monocyte/macrophage cell transcripts levels were found to be increased significantly
in spinal cord tissue from sporadic ALS patients compared to controls (Henkel et al.
2004). Previous research has shown that during systemic infection microglia recruit
monocytes into the brain through the release of TNF-α (D'Mello et al. 2009). In murine
models of Alzheimer’s disease bone marrow derived monocytes were demonstrated
to be recruited into the CNS (Simard et al. 2006). There is some evidence in mutant
SOD1 mice that the blood brain barrier is comprised at both early and late stages of
disease progression which could explain the presence of monocytes, T cells NK cells
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during ALS, which are not normally found in the CNS (Garbuzova-Davis et al. 2007,
Zhong et al. 2008).

1.8. Disease propagation and extracellular aggregated mutant SOD1 in ALS
While SOD1 is normally an intracellular protein it can also be found outside cells.
Evidence of SOD1 secretion is now widespread; SOD1 has been shown to be
secreted from various cell types including neuroblastoma (Mondola et al. 1998), thymic
derived (Cimini et al. 2002), pituitary derived (Santillo et al. 2007), hepatocyte and
fibroblast (Mondola et al. 1996) lines. More importantly it has also been shown to be
secreted from a motor neuron cell line (Turner et al. 2005, Gomes et al. 2007), in
cerebrospinal fluid of mutant SOD1 rats (Turner et al. 2005), in primary spinal cord
cultures of mutant SOD1 mice (Urushitani et al. 2006), in blood plasma (Mondola et
al. 2000) and in the cerebrospinal fluid of humans with familial ALS (Jacobsson et al.
2001).

As outlined previously, mutant SOD1 has been shown to inhibit the proteasome
(Uversky et al. 2002). When this occurs, cells increase the rate at which they secrete
mutant SOD1 (Urushitani et al. 2006). The secretion of mutant SOD1 is mediated by
chromogranin interaction (Urushitani et al. 2006). Chromogranins are components of
neurosecretory vesicles that are transported in the trans-Golgi network to the cell
membrane (Rudolf et al. 2001, Taupenot et al. 2003). This mechanism may explain
how mutant SOD1 escapes its intracellular environment (Urushitani et al. 2006).
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Mutations to SOD1 have been shown to make it more aggregation prone and
mutations in the SOD1 gene are found in a number of familial forms of ALS. In fact
aggregation is a common feature in many late onset neurodegenerative diseases
including Alzheimer’s disease and Parkinson’s disease. In these neurodegenerative
diseases, microglial receptors have also been shown to interact with protein
aggregates suggesting that it possible that these two features are be linked (Table
1.3).
Table 1.3: Evidence of receptors shown to interact with aggregated protein and
microglia in neurodegenerative diseases
Disease and associated
aggregate protein

Alzheimer’s
Aβ

Parkinson’s
α-synuclein

Amyotrophic lateral
sclerosis
mutant SOD1

Receptor protein
interaction in microglia
The scavenger receptor for
advanced glycation end
products (RAGE)
Pyrin domain-containing 3
(NLRP3)

(Deane et al. 2003)

Scavenger receptors (SR-A
SR -B)

(Murgas et al. 2012)

Receptor Complex
(CD36,CD47,ɑ6β1 integrin)

(Bamberger et al. 2003)

FPRL1/FPR2

(Le et al. 2001)

Scavenger receptor CD36

(Coraci et al. 2002)

Toll-like receptors (TLRs) 24

(Reed-Geaghan et al. 2009)

CD14

(Reed-Geaghan et al. 2009)

CD33

(Malik et al. 2013)

Toll-like receptor 2

(Kim et al. 2013)

Scavenger receptor CD36

(Su et al. 2008)

Reference

(Halle et al. 2008)

Scavenger receptor
(Roberts et al. 2013)
CD14
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A common hallmark of ALS disease is focal onset followed by a continuous
progression of pathology along an anatomical pathway (Ravits and La Spada 2009).
Non-ALS related proteins (prion proteins, Tau and α-synuclein) have also been shown
to demonstrate anatomical spreading (Clavaguera et al. 2009, Sanders et al. 2014,
Peelaerts et al. 2015). In cell culture SOD1 and TDP-43 aggregates have recently
been shown to exhibit prion like properties seeding aggregation and spreading from
neuron to neuron (Grad et al. 2014, Feiler et al. 2015).

Figure 1.4: ALS progression and propagation. ALS disease begins with focal onset
(involving upper and lower motor neurons) followed by a continuous spread along an
anatomical pathway as the disease progresses (Ravits and La Spada 2009).

Recent studies have shown that SOD1 aggregates in motor neurons can escape the
intracellular environment during cell motor neuron death and via exosomes (Grad et
al. 2014). This secretion of aggregated mutant SOD1 is thought to be an attempt to
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detoxify the cell, by stopping the accumulation of aggregated protein and thus cell
death. SOD1 aggregates appear in astrocytes and inhibitory interneurons in close
proximity to motor neurons only after inclusion formation in motor neurons in SOD1G93A
mice (Rossi et al. 2008, Hossaini et al. 2011). Further, WT astrocytes transplanted into
mutant SOD1 mice acquire inclusions (Lepore et al. 2008). This is consistent with the
idea that SOD1 aggregates can be released from motor neurons and subsequently
taken up by nearby cells. Mounting evidence suggests that microglia and astrocytes
contribute to motor neuron death in ALS but what activates these cells remains
unknown. One possibility is that protein aggregates formed in motor neurons are
subsequently released where they chronically activate microglia and astrocytes. There
is precedence for this phenomenon in other diseases such as Alzheimer’s disease
where amyloid fibrils activate both microglia and astrocytes.
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1.9. Aims
The overarching aim of this work is to examine the possibility that ALS associated
protein aggregates (using SOD1 as a model) can interact with and activate microglia
and astrocytes specifically:
1. Determine if ALS associated mutant SOD1 aggregates activate primary murine
microglia.
2. Determine if ALS associated mutant SOD1 aggregates cause dysfunction in primary
murine astrocytes.
3. Establish if extracellular aggregated mutant SOD1 mediates microglial activation
and astrocyte dysfunction in vivo.
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2. General Methods
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2.1 SOD1 purification
SOD1 was produced in E.coli using a plasmid containing both human SOD1 and its
copper chaperone (SOD1 plasmid was a kind gift from the Oliveberg group, Sweden)
as previously described (Lindberg et al. 2002). Briefly, cells were cultured at 23°C in
the presence of 3 mM CuSO4- and 30 μM ZnSO4- to ensure correct metal loading. The
SOD1 protein was further purified by heat denaturation and ammonium sulphate
precipitation. Samples were passed over a size exclusion column Superdex 75 (GE
Healthcare, UK) equilibrated with 50 mM Tris-HCl 500 mM NaCl buffer pH 7.5.
Samples were run at 0.5 mL/minute using 50 mM Tris-HCl 500 mM NaCl buffer pH
7.5. The size exclusion column was operated using AKTA FPLC system (Amersham
Biosciences, UK). To analyse purity, a 15% SDS-gel was run under reducing
conditions (see chapter 2.2 SDS-PAGE) of relevant fractions, the fractions containing
putative SOD1 were pooled and dialysis performed against 10 mM Tris-HCl pH 7.5 at
4°C.

Protein sample pooled from size exclusion purification was direct loaded onto a QSepharose anion exchange column (GE Healthcare, UK) equilibrated with 10 mM TrisHCl pH 7.5 and eluted with a salt gradient of 0 - 125 mM NaCl pH 7.5. Prior to
equilibration, and after use, the column was washed with 10 mM Tris-HCl 1 M NaCl
pH 7.5 to remove any unwanted proteins still bound to the column. The column was
operated using AKTA explorer (Amersham Pharmacia Biotech, UK). To analyse purity,
a 15% SDS-gel was run under reducing conditions of relevant fractions. Fractions
containing putative SOD1 (which showed >95% purity) were pooled. Pooled fractions
were dialyzed against Phosphate buffered saline (PBS) (160 g/L NaCl, 4 g/L KCl, 22.3
g/L Na2HPO4 (anh), 4 g/L KH2PO4) overnight at 4°C before protein was concentrated
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with centricon (5000 Da Cut off) (GE healthcare, UK) to no greater than 10 mg/mL and
stored frozen at -20°C.

2.2 SDS-PAGE
SDS-PAGE electrophoresis 15% was performed using a Hoefer Mighty Small ΙΙ
system (Amersham Biosciences, UK), connected to a Bio-Rad power pack 300 power
supply (Bio-Rad, USA). Protein samples were combined with 4 × protein sample buffer
(0.04 % bromophenol blue, 8 % SDS, 40 % glycerol, 240 mM Tris-HCl, pH 8.8.), 1 μL
beta mercaptoethanol (for reducing conditions) and boiled for 5 minutes before loading
into wells. Molecular weight markers (Fermentas, Australia) were used to determine
the approximate size of bands.

Electrophoresis took place at 120 V until the dye front had reached the bottom of the
gel. The gel was then stained with Coomassie blue for 30 minutes. Following staining
the gel was destained with destain solution (40% (v/v) Methanol, 10% (v/v) Glacial
acetic acid, double distilled H2O to volume). Gels were scanned using a GS-800
Calibrated Densitometer (Bio-Rad, USA).

2.3 Protein quantification
To determine the original concentrations of the SOD1 samples a BCA assay was
performed. Bovine serum albumin (BSA) (Sigma Aldrich, USA) was used to make
protein standards between 0 – 1 mg/mL, which were added to 384 well microplate
(Greiner bio-one, USA) in triplicate. A binary dilution of each protein was then carried
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out in triplicate on the same plate. BCA working reagent (Sigma Aldrich, USA) was
prepared and 80 μL was added to each well. The plate was then incubated at 37°C
for 30 minutes before the absorbance was read at 592 nm using a Spectra Max Plus
384 spectrophotometer. A standard curve was prepared using the BSA standards and
protein concentrations determined via extrapolation.

2.4 Endotoxin removal
Endotoxin was removed from the recombinantly produced SOD1 using an Endotrap
red column (Hyglos, Germany) following the manufacturer’s instructions. Briefly, the
column was regenerated using regeneration buffer (commercial buffer based on PBS
pH 7.4), equilibrated, using Equilibration buffer (10mM Na2HPO4, 80mM NaCl,
pH7.4), before the sample was passed over the column twice to ensure sufficient
removal of endotoxin. Equilibration buffer used to elute entire sample.

2.5 Poly D Lysine coating of flasks and chamber slides
To aid in the adhesion of primary astrocytes and microglia to flasks and chamber slides
a Poly D Lysine coat (PDL) (Sigma Aldrich, USA) was used. Under sterile conditions
5 μg/mL of PDL in H2O was prepared and added to flasks and chamber slides (enough
to cover the surface area of each). PDL was allowed to adhere for 2 hours at 37°C
before being washed with sterile H2O. Flasks and chamber slides were then allowed
to dry in a biosafety cabinet before use.
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2.6 Papain solution
A papain solution was prepared fresh for the enzymatic breakdown of mouse cortex.
Papain solution was prepared by dissolving papain (Worthington, USA) (final
concentration of 1 mg/mL), L-cysteine (240 μg/mL) and 100 μg/mL DNase I type IV
(Sigma) into 1 mL of MEM-HEPES (25mM HEPES). The resulting solution was then
incubated at 37°C for 30 minutes before use.

2.7 Western blotting
To confirm the identity of SOD1 after purification and to determine internalisation of
biotinylated aggregated SOD1G93A, western blots were performed. SDS-PAGE
analysis was performed under reducing conditions (as described above) with prestained markers (Fermentas, Australia). Western transfer was then performed, onto
nitrocellulose membrane (Biotrace, Mexico), utilizing fibre pads and blotting paper presoaked in western transfer buffer (3.1 g Tris base/L, 14.4 g glycine/L, 20 % (v/v)
methanol). The trans-blot apparatus was placed in the Mini-Protean II electrophoresis
cell (Bio-Rad, USA) which was filled with western transfer buffer. The transfer was
performed at 100 V for 1 hour at 4°C, while stirring, using the Bio-Rad power pack 300
power supply (Bio-Rad, USA). After transfer, the nitrocellulose membrane was placed
in heat denatured casein (1% (w/v) heat denatured casein and 0.01% (w/v) thimerosal
in PBS) overnight to block unreacted sites, before western blotting was undertaken.
The membrane was washed with PBS triton X-100 0.1% before each antibody
treatment (anti-SOD1 1:1000, secondary HRP 1:1000) and the chemiluminescent was
detected using the enhanced chemiluminescence kit (Pierce, USA) and Amersham
Hyperfilm (GE Healthcare, UK).
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To determine levels of BiP from cell lysates western blots were also performed under
slightly different conditions to those described above. The transfer was performed at
24 V overnight at 4°C, while stirring, using the Bio-Rad power pack 300 power supply
(Bio-Rad, USA). After transfer, the nitrocellulose membrane was rinsed in TBST (Tris
Buffer Solution Tween; 14.61g NaCl/L, 1.18g Tris/L, 6.35 g Tris HCl/L, 2mL Tween per
liter of milli Q at pH 7.5) and placed in TBST containing 5% milk powder for blocking
(Diploma, New Zealand). The membrane was washed with TBST before each
antibody treatment (anti BiP 1:1000, secondary 1:500) and the chemiluminescent was
detected using the enhanced chemiluminescence kit (Pierce, USA) and Amersham
Hyperfilm (GE Healthcare, UK).

2.8 Cytokine release
To test for cytokine release of three major cytokines observed to be upregulated in
ALS TNF-α and MCP-1 and IL-6 were measured (Sekizawa et al. 1998, Poloni et al.
2000, Nagata et al. 2007). Supernatant was obtained from microglia and primary
astrocyte cultures that had been treated with aggregated SOD1G93A (and supernatant
from positive and negative controls). Supernatants were then snap frozen using liquid
nitrogen and stored at – 80°C until assayed via ELISA. Mouse TNF-α, IL-6 and MCP1 ELISA Ready-Set-Go kits (ebiosciences USA) were used to measure the amount of
cytokine released from primary microglia and astrocytes.

Briefly, a Corning Costar ELISA plate was coated with 100 μL/well of capture antibody
(1:250 dilution of purified anti-mouse IL-6 or MCP-1 in coating buffer). The plate was
sealed and incubated overnight at 4°C. Wells were aspirated and washed and the
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plate blotted on absorbent paper. To block wells 200 μL/well of 1 × Assay Diluent was
added to the plate and incubated at room temperature for 1 hour. Wells were aspirated
and washed 5 times. Recombinant mouse IL-6 or MCP-1 standard (supplied with the
kit), was diluted to 1000 pg/mL and serially diluted (performed in triplicate final volume
of 100 μL/well) to make a standard curve. 100 μL of supernatant from the cells was
added to wells in triplicate the plate sealed and incubated at 4°C overnight. Wells were
aspirated and washed, 100 μL/well of detection antibody (biotin conjugate anti-mouse
TNF-α, MCP-1 or IL-6 1:250 dilution in 1 × assay diluent) was added, and the plate
was sealed and incubated at room temperature for 1 hour. Wells were washed as
previously described, before 100 μL/well of Avidin-HRP (1:250 dilution in 1 × assay
diluent). Plate was sealed and incubated at room temperature for 30 minutes. Wells
were aspirated and washed and 100 μL/well of substrate solution was added and the
plate incubated at room temperature for 15 minutes. 50 μL of stop solution was added
to each well. The absorbance of the wells at 450 nm was measured using a Spectra
Max Plus 384 spectrophotometer. A standard curve was prepared from the TNF-α, IL6 or MCP-1 standards and the levels of TNF-α IL-6 and MCP-1 determined.

2.9 Biotinylation of aggregated SOD1
For use in separate experiments (non-ELISA based experiments), Biotin reagent
was made up to a concentration of 40 mg/mL in DMSO. The biotin solution was then
combined with aggregated SOD1G93A using a 0.25 mg per mg of aggregated
SOD1G93A. This solution was then incubated with gentle agitation at room
temperature for 2 hours. Excess unbound biotin was removed via dialysis (3x) in
PBS pH 7.4.
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2.10 Mean fluorescent intensity determination of confocal images
Mean fluorescent intensity of confocal images was determined via image j software
analysis measuring mean fluorescence intensity per cell following a previously
published method (https://sciencetechblog.files.wordpress.com/2011/05/measuringcell-fluorescence-using-imagej.pdf).
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3. Extracellular
aggregated Cu/Zn
superoxide
dismutase
activates microglia
to give a cytotoxic
phenotype
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This chapter is based on a peer reviewed journal (with slight adaptations) published
in the journal Glia in 2013.

Roberts K, Zeineddine R, Corcoran L, Li W, Campbell IL, Yerbury JJ. (2013)
Extracellular aggregated Cu/Zn superoxide dismutase activates microglia to give a
cytotoxic phenotype. Glia. 61 (3), 409-419.
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3.1 Introduction
Amyotrophic lateral sclerosis (ALS) is a devastating motor neuron disease
characterised by the selective death of motor neurons in the motor cortex and spinal
cord. Motor neuron death is associated with the formation of protein inclusions and
activation and proliferation of astrocytes and microglia (Pasinelli and Brown 2006).
The actual cause(s) of most cases of ALS are undefined, however approximately 10%
of cases are inherited (familial ALS; fALS). The best-studied fALS cases are from
families possessing mutations in the gene encoding copper/zinc superoxide
dismutase (Cu/Zn SOD, SOD1). It is thought that mutant SOD1 causes pathology
through a toxic gain of function and there is increasing evidence that the misfolding of
mutant SOD1 underlies disease pathology (Wang et al. 2002). The precise
mechanism by which SOD1 mutants are toxic is unknown. Recent research
demonstrates the importance of non-neuronal cells, such as microglia, in disease
progression (Pramatarova et al. 2001). In fact, activation of microglia can be observed
before the onset of weakness and significant motor neuron loss in transgenic mice
expressing human mutant SOD1 (Alexianu et al. 2001). Data from experiments
conducted in wild type/mutant SOD chimeric mice demonstrate that mice with wild
type glial cells live longer, suggesting that glial cells containing mutant SOD1
contribute to disease (Clement et al. 2003). Microglial activation in mutant SOD1 mice
increases throughout the duration of the disease and remains evident in the late
stages of the disease (Hall et al. 1998, Alexianu et al. 2001, Henkel et al. 2006).

Recent work demonstrates that mutant SOD1 can be secreted into the extracellular
environment, where it is toxic to motor neurons via activation of microglia (Urushitani
et al. 2006). This indirect toxicity is likely to be due to the secretion of toxic mediators
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such as reactive oxygen species (ROS), proinflammatory cytokines and glutamate
(Bal-Price and Brown 2001, Henkel et al. 2006). Evidence for mutant SOD1 secretion
is now widespread; mutant SOD1 has been shown to be secreted from a range of cell
types (COS-&/NIH3T3 cells (Urushitani et al. 2006), hepatocyte and fibroblast
(Mondola et al. 1996), neuroblastoma (Mondola et al. 1998), thymic derived (Cimini et
al. 2002), and pituitary derived (Santillo et al. 2007). In addition, and more importantly,
it has also been shown to be secreted from a motor neuron cell line (Turner et al. 2005,
Gomes et al. 2007), primary spinal cord cultures from mutant SOD1 expressing mice
(Urushitani et al. 2006), and has been found in cerebrospinal fluid (CSF) of mutant
SOD1 rats (Turner et al. 2005), in blood plasma (Mondola et al. 2000) and in CSF
(Jacobsson et al. 2001) of fALS patients.

Although SOD1 forms intracellular inclusions, there are lines of evidence that suggest
that SOD1 aggregates can escape the intracellular environment. SOD1 aggregates
appear in astrocytes and inhibitory interneurons in close proximity to motor neurons
only after inclusion formation in motor neurons in G93A mice (Rossi et al. 2008,
Hossaini et al. 2011) consistent with their release and subsequent uptake. In addition,
one report has established that approximately 6-7% of transplanted wt astrocytes were
found to contain detectable ubiquitin positive inclusions after transplantation in mutant
SOD1 mice (Lepore et al. 2008). Moreover, a recent report has demonstrated that in
N2a cells in culture SOD1 aggregates can transfer from cell to cell, requiring a release
of aggregates (Munch et al. 2011). Regardless, during phagocytic removal of dead or
dying motor neurons during ALS microglia will inevitably encounter inclusions of
aggregated

protein.

Since

protein

aggregates

associated

with

other

neurodegenerative diseases such as Alzheimer’s can activate microglia (Casal et al.
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2002), we wondered whether SOD1 protein aggregates would also effectively trigger
microglia activation. In the current study we investigated the response of microglia to
SOD1 aggregates compared to that of soluble wild type and mutant SOD1. We show
that aggregated SOD1 is a potent activator of microglia, for the first time linking protein
aggregation and gliosis in ALS.
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3.2 Methods
3.2.1 EOC.13 cell cultures
LADMAC (American type culture collection, USA) and EOC.13 (American type culture
collection, USA) cells originally frozen in liquid nitrogen were thawed quickly in a
container with ethanol which was placed in 37°C water bath. Cells were then
transferred to 15 mL falcons which were topped up to 10 mL with Dulbecco’s Modified
Eagle Medium F12 (DMEM:F12) (Invitrogen, Australia) before being pelleted in a
bench top centrifuge for 5 minutes at 301 g at 22°C. Supernatant was then removed
and 5 mL of growth media (see below) was used to resuspend cell pellets.

LADMAC cells growth media contained 10% Foetal Bovine Serum (FBS) (Bovogen
Biologicals Australia) and 90 % DMEM: F12. In the case of EOC.13 cells growth media
contained 10 % FBS, 20 % LADMAC conditioned media (containing the necessary
Colony Stimulating Factor 1 (CSF-1)) and 70% DMEM F12. Cells were then transfer
to a T-25 tissue culture flasks (Greiner bio-one, Germany) and grown in a CO2
incubator at 37°C until 80 % confluent.

LADMAC conditioned media was generated by culturing LADMAC cells until they were
80 % confluent and subsequently incubating for 3-5 days and collecting the
supernatant. The collected supernatant was then removed and filtered for use in
EOC.13 growth media or frozen at -20°C until needed.

3.2.2 Primary microglial cell cultures
Primary microglial cultures were prepared as described previously (Carter et al. 2007).
Briefly, postnatal mouse forebrain (days 1–2) was stripped of meninges, finely
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chopped, and dissociated in papain before being cultured for 7-10 days on poly-dlysine -coated culture flasks in DMEM (Invitrogen, Australia) supplemented with 10%
FBS. After establishment of the astrocyte monolayer, flasks were shaken for 1 h to
obtain enriched microglia cultures (Figure 3.1).

3.2.3 Purification of recombinant SOD1
See Chapter 2.

3.2.4 SOD1 aggregation
Purified SOD1G93A protein was incubated at 0.5 mg/mL in 10 mM KH2PO4 in the
presence of 20 mM Dithiothreitol (DTT), 5 mM Ethylenediaminetetraacetic acid
(EDTA) at 37°C and a pH of 7.4 whilst shaking for 62 hours. For thioflavin T
measurements the same conditions were used with the addition of 50 μM Thioflavin
T. Solutions were added to a 384 well microplate and fluorescence was examined
using a Polarstar omega (BMG Labtech, Australia) fluorescent plate reader using an
emission filter of 490 +/- 10 nm and excitation filter of 440 +/- 10 nm.
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Figure 3.1: Experimental outline of primary microglia culture preparation.
Mating’s were set up between wildtype C57BL/6 mice and after 3-4 weeks pups were
obtained. Brain tissue was then harvested from 1-2 day pups, meninges removed and
cortex digested using papain. Cells were then cultured for one week before cells were
split and cultured for a future 2 weeks before microglia were obtained by shaking at
225 rpm for 3 hours.
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3.2.5 Circular Dichroism
All samples were dialysed against 10 mM Na2HPO4, pH 7.4 at 4°C. Samples were
analysed using the Jasco Model J-810 spectropolarimeter linked to a CDF-4265/L
Peltier system (Jasco, Canada), with 6 reads used to obtain an average spectrum.
Spectra of phosphate buffer alone was subtracted from that of protein samples.

3.2.6 SOD1 enzymatic activity In-gel-zymography
SOD1 variants were loaded onto a 10% native PAGE gel which was run at 100 V for
2 hours at 4°C. The gel was then incubated with 0.6 mg/mL Nitroblue tetrazolium
(NBT) in the dark while rocking for 30 minutes and subsequently washed before being
incubated with 0.45% tetramethyl-ethlenediamine (TEMED) and 10 μg/mL riboflavin
and rocked for 30 minutes before being exposed to light.

3.2.7 Exogenous SOD1 treatment
In order to produce resting EOC.13 microglia, LADMAC supernatant was withdrawn
and the cells incubated in 10% FBS in DMEM: F12 for 72 hours before treatment. After
72 hours 5 μg/mL of recombinant SOD1 (WT, G93A soluble and aggregated) protein
or the same volume of PBS as a negative control were added to individual wells in 10
% FBS in DMEM: F12. Primary microglia were treated with 5 μg/mL of recombinant
SOD1 for 24 hours. Supernatants were collected at various timepoints over a 24 hour
period and snap frozen in liquid nitrogen and stored at -80oC. In some experiments
cells were pretreated with either 5 mg/ml polyinosinic acid (poly(i)) or a neutralising
anti-CD14 antibody (Abcam; 1 mg/ml). Mitosox Red was used as per the
manufacturer’s instructions to measure superoxide production in living cells
(Invitrogen, Australia), data was collected using FACS diva (BD Bioscience, USA) and
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analysed using Flow Jo (Tree star, USA). Cytokine concentration in supernatants were
measured using Ready-Set-Go kits (eBioscience, USA) as per the manufacturer’s
instructions (eBioscience, USA).

3.2.8 Cell surface binding
SOD1 protein was added to EOC.13 cells that had been removed from the flask with
5 mM EDTA in PBS. Cells were resuspended in Hank’s buffered salt solution (HBSS,
137 mM NaCl, 5.4 mM KCl, 0.25 mM Na2HPO4, 0.44 mM KH2PO4, 1.3 mM CaCl2, 1
mM MgSO4, 4.2 mM NaHCO3) containing either 20 μg/mL of SOD1 protein sample
(native SOD1G37R, SOD1G93A, SOD1A4V, SOD1WT and aggregated SOD1G93A,
SOD1A4V) or the unrelated intracellular enzyme GST or no protein as controls. Cells
were then incubated on ice for 30 minutes before being washed with HBSS. A 1:200
dilution of anti-Cu/Zn SOD1 rabbit antiserum in PBS containing 0.1 % BSA (Millipore,
USA) and subsequent sheep anti-rabbit-FITC (Chemicon, Australia) was used to
detect bound SOD1. In some instances cells were pretreated with with either 25 μg/ml
cytochalasin D, 100 μM EIPA or 5 mM MβCD or pretreated with either 500 μg/ml
Mannan, 300 μg/ml Fucoidan, 500 ng/ml LPS in PBS azide for 30 min at 4°C, followed
by 20 μg/mL of aggregated SOD1G93A for 30 min at 4°C. In the case of biotinylated
SOD1G93A and SOD1A4V aggregates, EOC.13 cells were incubated with 10 μg/ml SAAlexa 488 (Chemicon, Australia). Propidium iodide (Sigma Aldrich, USA) was added
to each sample just before analysis by flow cytometer for exclusion of dead cells from
the analysis. Data was collected using FACS diva (BD Bioscience, USA) and analysed
using Flow Jo (Tree star, USA). Alternatively cells were grown on cover slips and
treated as above before being fixed using ice cold paraformaldehyde in PBS for 15
min at room temperature, washed in PBS and subsequently mounted in Citifluor AF1
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(Citifluor, UK) and imaged using a Leica TCS confocal scanning microscope (Leica,
Germany).

3.2.9 Cell viability assays
Conditioned media from aggregated SOD1G93A treated primary microglia were added
to NSC-34 cells to make a final concentration of 50% (v/v). NSC-34 cells were
incubated in 50% conditioned media for 48 hours before using calcein-AM as a probe
for cell viability. Briefly, cells were exposed to 1 μM calcein-AM and incubated at 37oC
for 30 min. After 30 min the fluorescence of the wells (485+/-10 nm excitation and
520+/- 10 nm emission) was measured using a fluostar optima microplate reader. In
some experiments cells were co-treated with a neutralizing anti-TNF-α antibody
(Abcam), hemoglobin or SOD1WT.

3.2.10 Statistics
Data were expressed as mean +/- SEM. Statistical significance was evaluated with
one-way analysis of variance (ANOVA) followed by Tukey’s post hoc test using Prism
5.0 GraphPad Software (San Diego, CA). A value of P < 0.05 was considered
significant.
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3.3 Results

3.3.1 SOD1 aggregates at physiological pH and temperature to form fibrils
In order to examine the effect of exogenous SOD1 on microglia we purified
recombinant human SOD1 from E. coli. To confirm that the SOD1 was folded correctly
we used circular dichroism and in-gel zymography. Purified SOD1 had a CD spectra
(Figure 3.2A) similar to that reported previously (Stevens et al. 2010) consistent with
the purified product having a correctly folded secondary structure. In addition,
recombinant SOD1 was a functional superoxide scavenger (Figure 3.2B)
demonstrating a functional tertiary fold.

Consistent with work of others

(Chattopadhyay et al. 2008) we found that incubation of SOD1 with 20 mM DTT and
5 mM EDTA produced SOD1 aggregates that were thioflavin T positive (Figure 3.3C)
and contained fibrillar structures (Figure 3.2D). The kinetics of aggregation were
consistent with that of other fibril forming systems exhibiting a lag phase followed by
growth phase and subsequent plateau (Figure 3.2C). We observed that the more
pathogenic variant A4V had a higher propensity to aggregate than did the G93A
variant. Under the conditions tested we did not observe any significant aggregation of
the wild type SOD1 (Figure 3.2C).
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Figure 3.2: Recombinant mutant SOD1 is more aggregation prone than wt SOD1.
A: Circular dichroism spectrum of 5 μM purified SOD1 proteins (SOD1A4V, SOD1G93A,
SOD1G37R, and SOD1WT) in 10 mM Na2HPO4, pH 7.4. B: In-gel-zymography assay
measuring enzymatic activity of SOD1A4V, SOD1G93A, SOD1G37R, and SOD1WT. A total
of 2 μM SOD1 samples were run at 100 V for 2 h at 4°C using native gel
electrophoresis. Gel was stained with NBT/Riboflavin/TEMED to determine dismutase
activity with achromatic bands indicating activity. C: Aggregation of SOD1 was
measured using a thioflavin T assay. Purified SOD1 was incubated at 0.5 mg/mL in
10 mM KH2PO4 in the presence of 20 mM DTT, 5 mM EDTA, and 50 μM thioflavin T.
D: TEM micrograph of SOD1G93A at 0.5 mg/mL incubated in 10 mM KH2PO4, 20 mM
DTT, 5 mM EDTA was loaded onto a carbon-coated nickel grid and negatively stained
using 2% (w/v) uranyl acetate.

3.3.2 Aggregated SOD1 activates EOC.13 cells
EOC.13 cells were used in this study as a model for microglia to exclude any artefacts
caused by LPS contamination introduced from bacterially produced recombinant
SOD1. EOC.13 cells are derived from the C3H/HeJ mouse (TLR4 defective) and thus
are unresponsive to LPS (Walker et al. 1995). Previous studies have found that soluble
mutant SOD1 incubated with primary microglia can increase TNF-α secretion
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compared to wild type SOD1 in a CD14/TLR4 dependant mechanism (Urushitani et
al. 2006, Zhao et al. 2010) however, the lack of CD14 in mice did not decrease
microglia activation suggesting that there may be other receptors involved in vivo. The
fact that the EOC.13 model is TLR4 defective makes it a useful model for identifying
other activation pathways. In the current study recombinant human SOD1, either
aggregated or soluble and correctly folded, was added to cells and incubated for 24
hours. The cell supernatants were then examined for TNF-α content. We found that in
the presence of SOD1, EOC.13 cells increased TNF-α secretion (Figure 3.3) in a
fashion that was consistent with the SOD1 mutants aggregation propensity
(WT<G37R<G93A<A4V SOD1; 16.91 +/- 0.62, 17.72 +/- 0.9897, 21.08 +/- 0.9179, 22
+/- 2.479 respectively). However, these differences were not statistically significant.
When EOC.13 cells were incubated with aggregated G93A or A4V SOD1 there was a
> 5 fold increase in TNF-α levels found in supernatant (Figure 3.3). Indicating that
aggregated SOD1 is a much more efficient activator of EOC.13 cells when compared
to soluble SOD1. In addition, incubation of EOC.13 cells with aggregated SOD1
increased ROS production as measured by mitosox red (Figure 3.4). The specific
ability of aggregated SOD1 to trigger TNF-α secretion was time (Figure 3.5) and
concentration dependant (Figure 3.6). In this model the appearance of TNF-α in the
supernatant was independent of both MCP-1 and IL-6 (Figure 3.7).
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Figure 3.3: Aggregated SOD1 induces TNF-α release from EOC.13 microglia.
Microglial cell line EOC.13, were grown for 72 h in the absence of CSF-1 followed by
incubation with 5 μg/mL SOD1 (SOD1WT, SOD1G37R, SOD1G93A, SOD1A4V and
preaggregated SOD1G93A and SOD1A4V). The supernatants were harvested at 24 h,
and at intervals, and TNF-α levels measured with Mouse TNF-α ELISA Ready-Set-Go
kit. *Denotes statistically significant increase when compared with WT SOD1-treated
cells (P < 0.05). (Work performed during honours included in (Roberts et al. 2013).

Figure 3.4: Incubation of EOC.13 cells with aggregated SOD1 increases ROS
production. Microglial cell line EOC.13, were grown for 72 h in the absence of CSF1 followed by incubation with 5 μg/mL SOD1 (SOD1WT, SOD1G93A, and preaggregated
SOD1G93A). Mitosox red fluorescence was measured using flow cytometry. *Denotes
statistically significant increase when compared with wild type SOD1-treated cells (P <
0.05).
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Figure 3.5: TNF-α secretion triggered by aggregated SOD1 is time dependant.
Microglial cell line EOC.13, were grown for 72 h in the absence of CSF-1 followed by
incubation with 5 μg/mL SOD1 (SOD1WT, SOD1G93A and preaggregated SOD1G93A).
The supernatants were harvested at 24 h, and at intervals, and TNF-α levels measured
with Mouse TNF-α ELISA Ready-Set-Go kit.

Figure 3.6: TNF-α secretion triggered by aggregated SOD1 is concentration
dependant. EOC.13 cells were incubated with 5–100 μg/mL aggregated G93A SOD1
for 24 h and supernatants collected and analyzed for TNF-α levels. *Denotes
statistically significant increase when compared with wild type SOD1-treated cells (P <
0.05).
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Figure 3.7: TNF-α in the supernatant was independent of both MCP-1 and IL-6. AB: EOC.13 cells were incubated with 5 μg/mL SOD1 for 24 hours and supernatants
collected and analysed for MCP-1 and IL-6 levels.

3.3.3 Aggregated SOD1 interacts with cell surface and is internalised by
EOC.13 cells
Given that aggregated mutant SOD1 promoted a TNF-α response from the EOC.13
cells we sought to characterise their interaction with aggregated SOD1. To determine
if aggregated SOD1 would bind to the cell surface it was incubated with cells on ice
for 30 minutes before subsequent immunodetection. Using both flow cytometry and
confocal microscopy we observed substantial binding of SOD1 to the cell surface of
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EOC.13 cells (Figure 3.8 A & B). We observed an increase in fluorescence for
aggregated SOD1 treatments (geomean of 25.4) (Figure 3.8 B). However, no binding
of the control protein GST was detected (geomean of 4.97 compared to 4.71 for no
treatment controls). Confocal microscopy revealed that the fluorescence detected was
initially present at the surface of the cell (Figure 3.8 A; 30 minutes). However, after 60
minutes of incubation the recombinant human SOD1 was no longer detected on the
cell surface (Figure 3.8 A, Non-permeabilised), but was detected inside cells after
permeabilisation. Cell lysates of EOC.13 cells treated with aggregated SOD1 confirm
uptake of aggregates (Figure 3.8 C). In addition, the aggregates remain in cells even
after 24 hours with minimal degradation (Figure 3.8 C).

3.3.4 Inhibition of lipid raft formation and scavenger receptors reduces the
aggregated SOD1 binding to EOC.13 cells
In an attempt to further characterise the binding and internalisation of SOD1
aggregates to EOC.13 cells we first tested a small panel of endocytosis inhibitors. We
pre-incubated EOC.13 cells with either cytochlasin D, EIPA or MβCD which are
inhibitors of actin cytoskeleton rearrangement, macropinocytosis and lipid raft
formation respectively. Only pre-treatment with MβCD was able to decrease the
amount of SOD1 aggregate binding. Moreover, using confocal microscopy of
permeabilised cells as a measure of internalisation, only pre-treatment with MβCD was
able to inhibit internalisation of aggregated SOD1 (Figure 3.9). In addition, to narrow
down the receptor(s) that may be important to aggregated SOD1 binding to the cell
surface we pre-incubated cells with either LPS, fucoidan or mannan to compete for
binding to the LPS receptor, scavenger receptors and mannose receptors
respectively. Pre-incubation of cells with fucoidan was able to significantly (p < 0.05)
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supress the amount of cell surface binding of aggregated SOD1. Although the amount
of aggregated SOD1 bound to cells was decreased by pre-incubation with LPS this
was not significant.

Figure 3.8: Aggregated SOD1 binds to the cell surface and is internalized into
EOC.13 microglia. A: Scanning confocal micrographs of aggregated SOD1 proteins
interacting with EOC.13 cells. Cells were incubated with 20 lg/mL of aggregated G93A
SOD1 for either 30 or 60 min on ice. At 30 min, cells were fixed and stained for human
SOD1. At 60 min, cells were either fixed or fixed and permeabilised before probing for
human SOD1. B: Quantitative analysis of the binding of SOD1 proteins to EOC13 cells
using flow cytometry after 30 min incubation on ice. In addition, control protein GST
(20 lg/mL) was also added to the EOC.13 cells for 30 min on ice and cells subsequently
probed for GST binding. Results are geometric means (standard error of triplicates
and are representative of at least three independent experiments. * Statistically
significant increase when compared with cells not treated with SOD1 (P < 0.05). C:
Western blot of cell lysates from EOC.13 cells incubated in the presence of SOD1
aggregates. Biotinylated SOD1 aggregates were added on to cells and incubated for
24 h. At various times, cells were lysed and lysates analysed by Western blot. SOD1
aggregates were reduced with b-mercaptoethanol and full length SOD1 and any
degradation fragments were detected using SA-HRP.
(Work performed by Rafaa Zeineddine included in (Roberts et al. 2013).
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Figure 3.9: Aggregate binding is dependent on lipid raft formation and scavenger
receptors. A: EOC.13 cells were pretreated with either 25 μg/mL cytochalasin D, 100
μM EIPA or 5 mM MβCD for 30 min at 4°C, followed by 20 μg/mL of aggregated G93A
SOD1 for 30 min at 4°C. Cells were then probed for human SOD1 and analyzed by
flow cytometry. Results are means ± standard error of triplicates and representative of
at least two independent experiments. * Denotes statistically significant difference (P
< 0.05). B: EOC.13 cells were pretreated with either 500 μg/mL Mannan, 300 μg/mL
Fucoidan, 500 ng/mL LPS in PBS azide for 30 min at 4°C, followed by 20 μg/mL of
aggregated G93A SOD1 for 30 min at 4°C. Cells were then probed for human SOD1
and analyzed by flow cytometry. Results are means ± standard error of triplicates and
representative of at least two independent experiments. * Denotes statistically
significant difference (P < 0.05). (Work performed by Rafaa Zeineddine included in
(Roberts et al. 2013).

3.3.5 Aggregated SOD1 interacts with and is internalised by primary microglia
Given that aggregated SOD1 interacted with EOC.13 cells we sought to characterise
the interaction of SOD1 aggregates with primary microglia. Due to the avidity of the
microglia to the coated culture dishes, we were unable to obtain meaningful flow
cytometry data. To determine if aggregated SOD1 would bind to the cell surface of
primary microglia, aggregates were incubated with cells on ice for 30 minutes before
subsequent immunodetection. Using confocal microscopy we observed substantial
cell surface fluorescence suggesting binding of SOD1 to the cell surface (Figure 3.10a;
quantified in g). After 60 minutes of incubation the aggregated SOD1 could be
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detected inside cells after permeabilisation (Figure 3.10b). To determine if the
mechanism of binding was similar to that of the EOC.13 cells we pretreated the cells
with either fucoidan, LPS or MβCD. In contrast to the EOC.13 cells we observe a
significant decrease of aggregated SOD1 binding after pre-treatment with LPS (Figure
3.10e & g) (p < 0.05). Consistent with our EOC.13 data we also observed a significant
decrease in internalised SOD1 after pre-treatment with fucoidan and a smaller but still
significant decrease after pre-treatment with MβCD (Figure 3.10c,d & g; p < 0.05).

Figure 3.10: Inhibition of mutant SOD1 binding in murine primary microglia.
Aggregate binding is dependent on lipid raft formation and scavenger receptors in
primary microglia. A-G: primary microglia cells were pretreated with either 25 μg/mL
cytochalasin D, 100 μM EIPA or 5 mM MβCD for 30 min at 4°C, followed by 20 μg/mL
of aggregated G93A SOD1 for 30 min at 4°C. Cells were then probed for human SOD1
and analyzed by confocal microscopy. G: Results are means ± standard error of
triplicates and representative of at least two independent experiments. * Denotes
statistically significant difference (P < 0.05). * Denotes statistically significant
difference (P < 0.05).
3.3.6 Aggregated mutant SOD1 activates primary microglia
To confirm that the aggregated SOD1 dependant release of TNF-α is not restricted to
the EOC.13 cell line we examined the ability of aggregated SOD1 to stimulate TNF-α
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release from primary microglia. To minimise LPS contamination we used LPS affinity
chromatography to separate any remaining LPS from the preparations. In addition,
recombinant wild type SOD1 purified in the same manner was used as a negative
control. Consistent with previous work (Urushitani et al. 2006, Zhao et al. 2010) we
found that G93A SOD1 elicited a significantly increased TNF-α response from
microglia compared to wild type SOD1 (p<0.05). Importantly, when compared to the
mutant SOD1 dependant response we observed that pre-aggregated G93A SOD1
promoted a >3 times greater increase in secreted TNF-α over the same time period.
This was significantly greater than TNF-α released after both wild type and mutant
SOD1G93A treatment of primary microglia (p<0.05) (Figure 3.13). In contrast to the
EOC.13 model the aggregated SOD1 also induced an increase in MCP-1 release from
primary microglia (Figure 3.11). In addition, aggregated SOD1 induced significant
increases in superoxide production as measured by mitosox red (Figure 3.12). In order
to verify that TNF-α release was dependant on lipid raft, scavenger receptor and CD14
dependant mechanisms we pre-incubated cells with either the scavenger receptor
ligand polyinosinic acid, or a CD14 neutralising antibody. Polyinosinic acid was used
in this assay as fucoidan and MβCD were both toxic to cells over an extended period
(data not shown). TNF-α release increased after treatment with aggregated SOD1G93A,
however it also was increased after incubation with polyinosinic acid when added
alone, as a result pre-treatment with this ligand did not inhibit TNF-α release. In
contrast, TNF-α was decreased when cells were pretreated with anti-CD14 (Figure
3.14). While our data suggests that the uptake of aggregates, and thus
proinflammatory response could be blocked by both scavenger receptors and CD14,
we confirm this occurs only in the case of CD14.
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Figure 3.11: Aggregated SOD1 induces MCP-1 release from primary microglia.
A-B: Primary microglia cells, were incubated with 100 μg/mL SOD1 (SOD1WT,
SOD1G37R, SOD1G93A, SOD1A4V and preaggregated SOD1G93A). The supernatants
were harvested at 24 h, and cytokine levels measured with Mouse IL-6 and MCP-1
ELISA Ready-Set-Go kits. *Denotes statistically significant increase when compared
with wild type SOD1-treated cells (P < 0.05).
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Figure 3.12: Aggregated SOD1 induces increased superoxide production in
primary microglia. A-D: Primary microglia cells, were incubated with 100 μg/mL
preaggregated SOD1G93A. The superoxide production was measured using mitox red.
*Denotes statistically significant increase when compared with wild type SOD1-treated
cells (P < 0.05).

3.3.7 Aggregated SOD1 induces release of soluble neurotoxic factor
Since microglial activation has been implicated in toxicity of extracellular mutant SOD1
on mixed primary brain cultures we took the supernatants of SOD1 activated microglia
and added them to mouse motor neuron like NSC-34 cells. After 48 hours of incubation
the viability of the cells treated with supernatant from aggregated SOD1G93A treated
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microglia had significantly dropped (~25%, p<0.05) (Figure 3.15). Although the viability
of cells incubated in soluble mutant G93A SOD1 induced microglia supernatant
dropped around 10% this was not significant. In an attempt to determine the toxic
factor in conditioned media we co-incubated either a neutralizing anti-TNF-α antibody
(5 μg/ml), 50 μg/ml hemoglobin or μg/ml wild type SOD1 with conditioned media to
block toxicity from TNF-α, nitric oxide and superoxide respectively. However, we
observed no change in cell viability after any of the pre-treatments used (Figure 3.16).

Figure 3.13: Aggregated SOD1 induces TNF-α release from primary microglia.
Primary microglia were incubated with 5 μg/mL SOD1 (SOD1WT, SOD1G93A, and preaggregated SOD1G93A) for 24 h. The supernatants were harvested at 24 h hours and
TNF-α levels measured with Mouse TNF-α ELISA Ready-Set-Go kit. Results are
means ± standard error of triplicates and representative of at least two independent
experiments. * Denotes statistically significant difference (P < 0.05).
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Figure 3.14: Blocking of CD14 receptor reduces the level of aggregated SOD1
induced TNF-α release from primary microglia. Primary microglia were pre-treated
with either polyinosinic acid or anti-CD14 antibody before incubation with 5 μg/mL preaggregated SOD1G93A for 24 h. The supernatants were harvested at 24 h and TNF-α
levels measured with Mouse TNF-α ELISA Ready-Set-Go kit. Results are means and
standard error of triplicate experiments. * Denotes statistically significant difference
(P < 0.05).

Figure 3.15: Soluble factors from primary cells are toxic to NSC-34 neuronal
cells. Supernatants collected from SOD1-treated primary microglia were added to
cultures of motor neuron like NSC-34 cells to give 50% v/v with fresh media. Cultures
were incubated for 48 h before analysing cell viability using Calcein-AM. Results are
means ± standard error of triplicates and representative of at least two independent
experiments. * Denotes statistically significant difference from PBS CM (P < 0.05).
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Figure 3.16: Aggregated SOD1 induces TNF-α release from primary microglia
which is toxic to motor neuron like NSC-34 cells. NSC-34 cells were treated with
either anti-TNF-α antibody, hemoglobin or wild type SOD1 before added in
combination with conditioned media from aggregated SOD1 (Agg. G93A CM)-treated
microglia or PBS-treated microglia (PBS CM). Results are means ± standard error of
triplicate experiments. * Denotes statistically significant difference (P < 0.05).
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3.4 Discussion
Two of the most prominent hallmarks of ALS pathology are: (i) inclusions consisting of
aggregated proteins and (ii) gliosis. There is accumulating evidence to suggest that
both protein aggregates (Watanabe et al. 2001, Wang et al. 2002, Wang et al. 2008,
Johnson et al. 2009, Fushimi et al. 2011, Guo et al. 2011) and glia play an active role
in ALS disease pathogenesis (Pramatarova et al. 2001, Clement et al. 2003, Turner
et al. 2004, Beers et al. 2006). However, there has been almost no attempt to link
these two aspects of disease. Although SOD1 inclusions are exclusively intracellular,
there is evidence that these inclusions can escape from the cytoplasm and come into
contact with nearby cells (Münch et al. 2011). Although extracellular soluble mutant
SOD1 has been shown to activate microglia (Urushitani et al. 2006, Zhao et al. 2010),
the effects of microglia coming into contact with SOD1 aggregates is unknown. Here,
we investigated the effect of aggregated SOD1 on microglial activation and
subsequent toxicity to motor neuron like cells. We show, for the first time, that microglia
become activated when they come in to contact with aggregated SOD1. Binding and
uptake of aggregated SOD1 can be inhibited by fucoidin and LPS, suggesting that
signalling is dependent on scavenger receptor and CD14 binding. We also show that
soluble factors secreted by aggregate activated microglia are toxic to motor neuron
like cells. These findings are consistent with aggregates released from dead or dying
cells playing a role in propagation of pathology in ALS.

All cases of ALS are associated with protein aggregates in the form of inclusions that
are found in surviving motor neurons or in nearby astrocytes (Miller et al. 2004). There
is a range of proteins that can be found associated with inclusions including gene
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products of some fALS genes such as FUS, TDP-43, Optineurin, Ubiquilin2, and
SOD1 (Neumann et al. 2006, Deng et al. 2010, Maruyama et al. 2010, Forsberg et al.
2011). SOD1 inclusions can only be found in SOD1 FALS cases, but recent work
suggests misfolded SOD1 can be found in SALS motor neurons (Bosco et al. 2010,
Forsberg et al. 2011). In this study, we used recombinant human SOD1 produced in
E. coli to examine the response of microglia to ALS associated aggregates. Circular
dichroism and enzymatic zymography demonstrated that human SOD1 used for this
study was correctly folded. The secondary structure measured in this study was similar
to that previously published (Stevens et al. 2010) and the purified protein showed
enzyme activity. Reduction of the disulphide bond and chelation of the metal ions
promoted aggregation of recombinant SOD1 as previously shown (Chattopadhyay et
al. 2008). A comparison of the rate of aggregation of three recombinant SOD1 mutants
showed that their aggregation propensity correlated with the rate of disease
progression with A4V being the most rapid and G37R the slowest (Wang et al. 2008).
Under the conditions tested, there was little aggregation from the wild type SOD1,
suggesting that the mutants are more aggregation prone. The aggregates produced
by these conditions included fibrillar structures as shown previously (Chattopadhyay
et al. 2008).

It has been established that SOD1 can be secreted from a range of cells and can be
found outside cells in vivo (Jacobsson et al. 2001, Turner et al. 2005, Urushitani et al.
2006). However, aggregates of SOD1 accumulate exclusively intracellularly, and there
is no evidence to suggest that the secreted SOD1 actively aggregates outside of cells.
Recent work demonstrates that SOD1 aggregates can escape the intracellular
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compartment, by an unknown mechanism, into the extracellular space (Münch et al.
2011). The consequences of this will be dependent on the cell type that the released
aggregates come in to contact with. In the example of neurons, it has been shown that
aggregates of mutant SOD1 can seed further aggregation of mutant SOD1 in natıve
neurons it has entered (Münch et al. 2011). In this study, although soluble SOD1, both
wild type and mutant, did not induce significant increases in EOC.13 cell activation,
aggregated G93A SOD1 promoted a fivefold increase in TNF-α release in these cells.
The response is dose dependant and can be detected as early as 6 h after addition of
aggregates. In addition, this response seemed to be independent of IL-6 and MCP-1
release in EOC.13 cells. EOC.13 cells treated with aggregated SOD1 also showed an
increase in ROS production suggesting that the response was not restricted to TNF-α
release.

To confirm that the observed effects of aggregated SOD1 were not restricted to a
single cell line, further studies were carried out using primary microglial cultures.
Previous studies had shown that microglia could become activated in the presence of
unaggregated mutant SOD1 (Urushitani et al. 2006, Zhao et al. 2010). Consistent with
this, we found that upon incubation with unaggregated mutant SOD1 primary microglia
significantly increased their secretion of TNF-α compared with those incubated with
SOD1WT. Consistent with our results from EOC.13 cells, primary microglia also
released significantly more TNF-α upon treatment with aggregated mutant SOD1
compared with SOD1WT or dimeric unaggregated SOD1G93A. In contrast, primary cells
also responded by releasing significant amounts of MCP-1 and increasing production
of superoxide. To eliminate any artefacts due to LPS, all recombinant protein was
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prepared using LPS affinity chromatography reducing the amount of any LPS present
in the sample. In addition, the fact that wild type and mutant SOD1 were purified under
identical conditions suggests LPS plays no role in the release of TNF-α in these
experiments. Further evidence that LPS is not involved is the fact that EOC.13 cells
do not respond to LPS but do respond to aggregated mutant SOD1. The data
presented here is the first example of ALS associated aggregates activating microglia.
However, it has been previously shown that microglia can be activated by aggregates
of Aβ (Casal et al. 2002, Maezawa et al. 2011) and α-synuclein (Zhang et al. 2005)
associated with Alzheimer’s disease and Parkinson’s disease, respectively.
Collectively, these data suggest that there may be a common feature of these
aggregates that is responsible for microglial activation. Although we only tested SOD1
aggregates it is likely that all ALS associated aggregates, including TDP- 43 positive
aggregates, activate microglia.

A range of receptors have been shown to play a role in the binding of protein
aggregates, such as those made from the amyloid-β (Aβ) peptide, to the cell surface
of microglia (Bamberger et al. 2003, Fu et al. 2012). Scavenger receptors CD36
(Coraci et al. 2002) and SR-A (ElKhoury et al. 1996), the receptor for advanced
glycation end products (RAGE) (Yan et al. 1996), integrin α6β1- integrin and integrin
associated CD47 (Bamberger et al. 2003), and CD14 and Toll-like receptors (TLR) 2/4
(Reed-Geaghan et al. 2009) have all been shown to be involved in microglial
interaction with aggregated Aβ. The interaction between microglia and protein
aggregate is generally not a simple one to one receptor to ligand interaction with many
receptors coming together to form large complexes that include signalling receptors
83 | P a g e

such as TLR2/4. This process of receptor complex formation, in some cases, is
dependent on membrane organization such as lipid raft formation (Zeng et al. 2003).
We show that aggregated SOD1 binding is inhibited by pretreatment with MβCD,
fucoidan, and LPS, suggesting that binding is dependent on lipid raft formation,
scavenger receptors and CD14. Scavenger receptors have been shown to
preferentially bind to proteins that have been modified by ROS or advanced glycation,
or chemical denaturants (Gowen et al. 2001, Horiuchi et al. 2003). In addition, fucoidan
has been shown to inhibit the binding of aggregated proteins such as Aβ (Fu et al.
2012) and misfolded proteins in complex with extracellular chaperones (Wyatt et al.
2011). Suggesting that scavenger receptors play an important role in binding to
misfolded or aggregated proteins in vivo. Although CD14 is best known for its ability
to bind and promote phagocytosis of pathogens, its pattern recognition capability is
likely to be responsible for binding to protein aggregates such as Aβ. We present data
here to suggest that CD14 is involved in the binding of aggregated SOD1 and thus
activation of and release of TNF-α by primary microglia. The data are consistent with
previous data suggesting that CD14 can form a large multireceptor complex that
include scavenger receptors, such as CD36 and SR-A, in the recognition of protein
aggregates such as those made from Aβ. These large complexes have been shown
to include signalling co-receptors such as the TLRs that trigger intracellular cascades
resulting in robust immune reactivity including TNF-α release (Reed-Geaghan et al.
2009). Thus, it is likely that the receptor complex involved with aggregated SOD1induced activation includes TLR co-receptors. Interestingly, in our EOC.13 model
activation was able to proceed in the absence of a functional TLR4 suggesting that
other TLR are also likely to be involved. Indeed, scavenger receptors such as CD36
can combine with TLR2/6 to produce responses to pathogen (Hoebe et al. 2005).
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It had previously been shown that extracellular mutant SOD1 was toxic to motor
neurons in culture. This was found to be dependent on microglia activation by
extracellular mutant SOD1. In this work, supernatants from microglia that have been
activated by contact with aggregated SOD1 were toxic to motor neuron-like cells in
culture consistent with a role of activated microglia in the cell death of motor neurons
in ALS. We used a neutralizing anti-TNF-α antibody, hemoglobin, and wild type SOD1
to suppress toxicity from TNF-α, nitric oxide, and superoxide, respectively. However,
we were unable to identify a specific toxic soluble factor. Although the toxic factor in
the supernatant is unknown, it remains possible that a combination of stressors could
be responsible for the loss of cell viability. Regardless, the release of toxic factors after
aggregated SOD1 dependant activation of microglia causes stress on motor neuronlike cells and may induce further release of protein aggregates causing a positive
feedback loop.

Research demonstrates the importance of non-neuronal cells in the pathogenesis of
ALS (Hall et al. 1998, Alexianu et al. 2001, Henkel et al. 2006). Current thought is that
there are fundamental differences underlying disease initiation and disease
progression in ALS. This line of thought is based on results showing that mutant SOD1
was important in neurons for disease initiation and in glia for disease progression in a
mouse model of ALS (Boillee et al. 2006). Although the role of protein aggregation in
disease pathology has not been clarified, SOD1 aggregates are certainly toxic to the
neurons they accumulate in culture (Matsumoto et al. 2005, Soo et al. 2009). It is
possible then that protein aggregation and inclusion formation are linked with the
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initiation event in ALS. The work presented here provides a potential link between
SOD1 aggregation and microglial activation, and thus provides evidence to suggest
protein inclusions may also be linked to disease progression. As a result, silencing
SOD1 aggregate induced microglial activation may be effective in slowing ALS
progression.
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4. Extracellular
aggregated Cu/Zn
superoxide dismutase
causes astrocyte
senescence
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4.1 Introduction
Amyotrophic lateral sclerosis (ALS) is a devastating motor neuron disease
characterised by the selective death of motor neurons in the motor cortex and spinal
cord. The actual cause(s) of most cases of ALS are undefined, however approximately
10% of cases are inherited (familial ALS; fALS). The best-studied fALS cases are from
families possessing mutations in the gene encoding copper/zinc superoxide
dismutase (Cu/Zn SOD, SOD1). It is thought that mutant SOD1 causes pathology
through a toxic gain of function, and there is increasing evidence that the misfolding
of mutant SOD1 underlies disease pathology (Wang et al. 2002). The precise
mechanism by which SOD1 mutants are toxic remains unclear.

It has previously been shown using co-culturing techniques that astrocytes play an
important role in the mutant SOD1 mouse model for ALS. In these studies, wild type
astrocytes were found to be beneficial to mutant SOD1 neurons when cultured
together (Yamanaka et al. 2008). Conversely, mutant SOD1 astrocytes were found to
cause wild type motor neuron degeneration in both mice and rat cultures (Yamanaka
et al. 2008, Diaz-Amarilla et al. 2011, Rojas et al. 2014). Astrocytes derived from ALS
patient post-mortem tissue, and induced pluripotent stems generated from ALS
patients’ fibroblasts, were also found to be toxic to motor neurons in cell culture
(Haidet-Phillips et al. 2011, Meyer et al. 2014). Transplantation of SOD1G93A glial
precursor cells, which differentiated into astrocytes, was shown to induce motor
neuron degeneration in mice (Papadeas et al. 2011). Interestingly, this study was able
to demonstrate in mice, that astrocyte dysfunction with reduced glutamate transport
expression accompanied the motor neuron loss (Papadeas et al. 2011). This
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dysfunction in astrocytes has also been previously demonstrated in motor cortex and
spinal cord tissue from ALS patients (Rothstein et al. 1995).

Recent studies have shown that SOD1 aggregates in motor neurons can escape the
intracellular environment during cell motor neuron death and via exosomes (Münch et
al. 2011, Grad et al. 2014). SOD1 aggregates appear in astrocytes and inhibitory
interneurons in close proximity to motor neurons only after inclusion formation in motor
neurons in SOD1G93A mice, (Rossi et al. 2008, Hossaini et al. 2011). Further, WT
astrocytes transplanted into mutant SOD1 mice acquire inclusions (Lepore et al.
2008). This is consistent with the idea that SOD1 aggregates can be released from
motor neurons and subsequently taken up by nearby cells. However, the effect of
uptake of inclusions on astrocytes remains unclear.

There is substantial evidence of endoplasmic reticulum stress occurring in neurons in
ALS patients and mutant SOD1 mice (Gonatas et al. 1992, Atkin et al. 2006, Atkin et
al. 2008, Saxena et al. 2009, Sun et al. 2015). In neuronal cells aggregated SOD1
has recently been shown be taken up via macropinocytosis, inhibit protein transport
between the ER-Golgi apparatus which leads to ER stress and cell death
(Sundaramoorthy et al. 2013, Zeineddine et al. 2015). When the endoplasmic
reticulum encounters misfolded proteins it mounts the unfolded protein response
(UPR) in an attempt to relieve stress (Korennykh et al. 2009). The UPR is comprised
of three main stress sensors, the transmembrane proteins PERK, IRE1 and ATF6
(Manie et al. 2014). Each of which activates downstream signalling pathways that
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reduce ER load and increase ER capacity to deal with misfolded proteins (Hetz 2012).
Inositol requiring enzyme 1 (Ire1), is a transmembrane protein which possesses both
kinase and endoribonuclease activity. The activation of Ire1 endoribonuclease activity
results in the excision of an intron from X-box binding protein (XBP-1). This causes a
frameshift in XBP-1 creating an alternate isoform which regulates the expression of
genes for protein quality control (Jaronen et al. 2014). This makes splicing of XBP-1 a
good target when identifying ER stress and subsequent UPR within cells. Researchers
have previously shown increased amount of spliced XBP-1 in neuron like cells
expressing mutant SOD1, indicating ER stress (Oh et al. 2008).

Since other types of protein aggregates associated with neurodegenerative diseases
such as Alzheimer’s have been shown to trigger both cell death (Brera et al. 2000)
and senescence in astrocytes (Bhat et al. 2012), we wondered whether mutant SOD1
protein aggregates effected astrocyte function and survival. In the current study we
investigated the effect of uptake and persistent presence of SOD1 aggregates had on
primary astrocytes. Our results demonstrate, for the first time, that aggregated SOD1
enters astrocytes via macropinocytosis, causing endoplasmic reticulum stress and
senescence and/or cell death. Based on these results it is proposed that protein
aggregates may directly contribute to astrocyte dysfunction and thus disease
progression in ALS.
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4.2 Methods
4.2.1 Primary astrocyte isolation
Primary astrocytes were prepared using the same steps during weeks 1 to 4 as
described previously for primary microglia. However at week 5 the mixed glial culture
was incubated with magnetic CD11b beads (to remove microglia) before being passed
over a macs sort column (Miltenyi Biotech, Australia) to isolate primary astrocytes
(Figure 4.1). To confirm pure cultures of primary murine astrocytes (as opposed to a
mixed glial culture) GFAP and CD11b antibodies (Millipore, Australia) were used to
analyse astrocyte and microglia populations within samples.

Figure 4.1: Experimental overview of extraction of primary astrocytes and
purification from mixed murine glial cultures. Cortex tissue from 1-2 day mice
pups was chopped up and digested with papain solution before established mixed
glial population was passed over a macs sorting column to obtain purified astrocyte
cultures.
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4.2.2 Freeze thaw lysis
Cells were harvested, washed in PBS and the cell suspension was centrifuged at top
speed (13,000xg) for 45 seconds before being resuspended in FT Lysis buffer (600mM
KCl, 20mM Tris-Cl, 20% Glycerol and protease inhibitor cocktail). Cells were then
frozen using liquid nitrogen and then thawed, this was repeated three times. After the
cell lysates was thawed, 250 units of DNase was added and incubated at room
temperature for 10 minutes. Protein concentration was then measured using a BCA
assay. Samples were then stored at -20°C until ready to use.

4.2.3 Astrocyte uptake of aggregated SOD1
Aggregated SOD1G93A with a biotin label was added to astrocyte cultures for 2 hours
at 37°C. Cells were washed 3 times with PBS (between each subsequent step) and
then fixed with 4% PFA for 15 minutes at room temperature. To permeabilise cell
membranes, tween 20 (0.5%) was added to the cells for 10 minutes. A 5% BSA
solution (in PBS) was added for 20 minutes to block non-specific binding. SA-Alexa488
diluted in PBS (1:500) (Chemicon, Australia) was added for 1 hour to detect
biotinylated aggregated mutant SOD1. To confirm the presence and purity of astrocyte
culture, cells were incubated with anti-mouse GFAP antibody raised in rabbit (1:300),
or rat anti-mouse CD11b (1:400) for 1 hour. Fluorophores anti-Rabbit Alexa 488 and
anti-Rat Alexa 488 (1:500) were added to cells and incubated for 1 hour. Cover slips
were added to slides using Mounting media (Prosci Tech, Australia) and CoverGrip
coverslip sealant (Biotium, USA) was used before slides were stored at -20°C. Slides
were imaged on the Leica TCS SP5 confocal microscope (Leica, Germany) using
imaging software LAS AF.
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Primary astrocytes were also allowed to settle and grow in 6 well plates (for 48 hours
before treatment). Cells were washed with PBS between each step of the experiment.
Aggregated SOD1G93A, soluble SOD1G93A, soluble SOD1WT (and PBS as a negative
control) was incubated with the cells for 2 hours at 37°C. Media was then replaced
and cells incubated in a CO2 incubator at 37°C for 72 hours. Cells were then lysed and
the protein concentration of each sample was measured using a BCA assay. 40 μg of
total protein/well was loaded onto an SDS page gel. Equal loading was confirmed by
examining total protein per lane and measuring actin levels across all samples using
an anti-actin antibody. Western blots were carried out incubating blots for 1 hour with
SA-Alexa488 (1:500) (Chemicon, Australia) to detect biotinylated aggregated
SOD1G93A.

4.2.4 Inhibition and detection of macropinocytosis
Primary astrocytes were grown on chamber slides (Lab Tek, Australia) for 48 hours in
DMEM with 10% FCS and pen-strep (Invitrogen, Australia). Cells were washed with
PBS between each step of the experiment. Inhibitors genistein (gen) (185 μM), methylbeta-cyclodextrin (MβCD) (5mM), chlorpromazine (CPZ) (5μM) or 5-(N-Ethyl-Nisopropyl) amiloride (EIPA) (100μM) were added to the astrocytes for 30 minutes at
37°C. Biotinylated aggregated SOD1G93A (100μg/mL) was added for 30 minutes at
37°C. Cells were then fixed with 4% PFA for 15 minutes at room temperature. To
permeabilise the cell membrane 0.5% triton X-100 in PBS was incubated with the cells
for 20 minutes at 4°C. A solution of 5% BSA in PBS was used to block non-specific
binding of antibodies. To probe for the biotinylated aggregated SOD1, SA-Alexa 488
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(1:500) was incubated with the cells for 60 minutes at 4°C. Treated primary astrocytes
were then imaged on the Leica TCS SP5 confocal microscope (Leica, Germany) using
imaging software LAS AF.

4.2.5 Detecting the cellular location of aggregated SOD1
Primary astrocytes were grown on coverslips for 48 hours in phenol free DMEM with
10% FCS and pen-strep (Invitrogen, Australia). Cells were washed with PBS between
each step of the experiment. The astrocytes were incubated with biotinylated
aggregated SOD1G93A for 2 hours at 37°C. Cells were then fixed using PFA 4% for 20
minutes at room temperature. To permeabilise all cell membranes, cells were
incubated with 0.5% triton X-100 in PBS for 30 minutes at 4°C. Alternatively, to
selectively permeabilise only the outer cell membrane, the cells were treated with 10
μM Digitonin (Holmuhamedov and Lemasters 2009) in PBS for 10 minutes at 4°C
(Figure 4.2). A solution of 5% BSA in PBS was used to block non-specific binding of
antibodies. To probe for the biotinylated aggregated SOD1, SA-Alexa 488 (1:500) was
incubated with the cells for 60 minutes at 4°C. Treated primary astrocytes were then
imaged on the Leica TCS SP5 confocal microscope (Leica, Germany) using imaging
software LAS AF.
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Triton X-100

Digitonin

Figure 4.2: Triton X-100 and digitonin permeabilisation of the cell membrane.
Triton X-100 permeabilises all cellular membranes allowing for detection of molecules
in the cytosol and in membrane bound compartments, whereas digitonin selectively
permeabilises only the plasma membrane allowing specific detection of cytosolic
molecules (green spots vs grey spots). This can be used to determine the cellular
location of molecules detected with fluorescently labelled antibodies (as marked on
the schematic as green).

4.2.6 ER stress

Primary astrocytes were grown on chamber slides for 48 hours in DMEM with 10%
FCS and pen strep (Invitrogen, Australia). Cells were washed with PBS between each
step of the experiment. The astrocytes were transfected with a XBP-1 Venus plasmid,
a reporter of ER stress, (2.5 μg/μL) using lipofectamine (Iwawaki et al. 2004) (Figure
4.3). The ER stress reporter contains Ire1 endoribonuclease splicing sites, which upon
activation of IRE1, the recombinant XBP-1 mRNA is spliced and results in an in-frame
translation of a venus fluorescent protein. Aggregated SOD1G93A, soluble SOD1G93A,
soluble SOD1WT (and PBS as a negative control) were incubated with the cells for 2
hours at 37°C. Media was then replaced and cells incubated in a CO 2 incubator at
37°C for 72 hours (protected from light). Cells were fixed with 4% PFA for 15 minutes
at room and stored at 4°C for 24 hours before imaging on the Leica TCS SP5 confocal
microscope (Leica, Germany) using imaging software LAS AF.
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Figure 4.3: Measuring endoplasmic reticulum (ER) stress using the XBP-1
reporter plasmid. After ER stress occurs, inositol requiring-1 (IRE-1) becomes
activated and splices the mRNA of XBP-1 producing a Venus fluorescent protein
(Iwawaki et al. 2004).

To further test for ER stress, levels of BiP were examined after treatment of primary
astrocytes with SOD1. An increase in levels BiP, from basal levels, is an established
indicator of ER stress (Oslowski and Urano 2011). Primary astrocytes were allowed to
settle and grow (using DMEM with 10% FCS and pen-strep) in 6 well plates for 48
hours before treatment. Cells were washed with PBS between each step of the
experiment. Aggregated SOD1G93A, soluble SOD1G93A, soluble SOD1WT (and PBS as
a negative control) were incubated with the cells for 2 hours at 37°C. Media was then
replaced and cells incubated in a CO2 incubator at 37°C for 72 hours. Cells were then
lysed and the protein concentration of each sample was measured using a BCA assay.
40 μg of total protein/well was loaded onto an SDS page gel. Equal loading was
confirmed by examining total protein per lane and measuring actin levels across all
samples using anti β-actin (1:1000). Western blots were carried out incubating blots
overnight at 4°C with rabbit anti-BiP and for 1 hour with goat anti rabbit Alexa HRP
(1:500) (Abcam, Australia).
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4.2.7 Astrocyte Senescence
Initially, to test for astrocyte senescence, cells were probed using a novel antibody
recognising a cell surface antigen increased on senescent cells (N. Cashman, Patent
pending). Aggregated SOD1G93A, soluble SOD1G93A, soluble SOD1WT (50 μM H2O2 as
a positive control and PBS as a negative control) were incubated with primary
astrocytes for 2 hours at 37°C. Media was then replaced and cells incubated in a CO2
incubator at 37°C for 72 hours. Cells were fixed before probing for senescent cells
using AMF-1c-120 a rabbit mAb (1:1000) (Courtesy of Neil Cashman) and an antirabbit Alexa 488 Ab (1:500) for 60 minutes at 4°C. Confocal microscopy and analysis
using image J was used to obtain the average mean fluorescence intensity across
triplicates.

To confirm astrocyte senescence a commercial β-Galactosidase staining kit was used
(Genesearch, Australia). Aggregated SOD1G93A, soluble SOD1G93A, soluble SOD1WT
(50 μM H2O2 as a positive control and PBS as a negative control) were incubated with
primary astrocytes for 2 hours at 37°C. Media was then replaced and cells incubated
in a CO2 incubator at 37°C for 72 hours. Cells were fixed and stained using the
commercial β-Galactosidase staining kit. Light microscope images of senescent
astrocytes were taken for each treatment. The absorbance of the 96 well plate was
then was read at 490 nm using a Spectra Max Plus 384 spectrophotometer to obtain
averages for 6 replicates (per treatment) of at least two independent experiments.
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4.2.8 Astrocyte cell death
Primary astrocytes were grown on chamber slides (company) for 48 hours in DMEM
with 10% FCS and pen strep (Invitrogen, Australia). Cells were washed with PBS
between each step of the experiment. Aggregated SOD1 G93A, soluble SOD1G93A,
soluble SOD1WT (and PBS as a negative control) were incubated with the cells for 2
hours at 37°C. Media was then replaced and cells incubated in a CO 2 incubator at
37°C for 72 hours. Cells were then treated as per the Image-iT Live Red Caspase
Detection Kit protocol (Invitrogen, Australia). Sytox green was used to stain nucleus
and Flica reagent was used to detect caspase activation.

In addition, primary astrocytes were allowed to settle and grow (using DMEM with 10%
FCS and pen strep) in 6 well plates for 48 hours before treatment. Cells were washed
with PBS between each step of the experiment. Aggregated SOD1 G93A, soluble
SOD1G93A, (and PBS as a negative control) were incubated with the cells for 2 hours
at 37°C. Media (phenol red free) was then replaced and cells incubated in a CO2
incubator at 37°C for 72 hours. Ethanol was added to cells and allowed to dry before
media was replaced (positive control for cell death with the highest reading designated
as 100% cell death). Propidium iodide (3 μM) was added to the cells before
determining the level of fluorescence (485 nm excitation, 620 nm emission) on the
FLUOstar OPTIMA plate reader (BMG Labtech).
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4.2.9 Statistics
Data is expressed as mean +/- SEM. Statistical significance was evaluated with either
an unpaired t-test, or a one-way analysis of variance (ANOVA) followed by Tukey’s
post hoc test using Prism 5.0 GraphPad Software (San Diego, CA). A value of P <
0.05 was considered significant.
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4.3 Results
4.3.1 Astrocytes take up aggregated SOD1
Given previous evidence that SOD1 inclusions can be found in astrocytes near to
motor neurons (Hovden et al. 2013) and that wild type transplanted astrocytes take up
aggregates in SOD1 mice (Lepore et al. 2008) the internalisation of aggregated
SOD1G93A in primary astrocytes was examined. An astrocyte culture of high purity was
confirmed (Figure 4.4 and 4.5) with a consistent lack of, or very little CD11b reactivity.
Using confocal microscopy it was observed, that incubation of aggregated SOD1G93A
(40 μg/mL) resulted in its association with GFAP positive cells in foci not present in
PBS treated controls (Figure 4.6). Additional experiments also demonstrated that
SOD1G93A protein aggregates stimulate a small but significant increase in GFAP when
added to astrocyte cultures (Figure 4.7). To confirm that the aggregates had entered
the cell, rather than bound to the cell surface, a cross sectional image of primary
astrocytes containing SOD1 aggregates was obtained. Aggregated SOD1G93A can be
seen within the boundary of the cell membrane, as determined by transmission
images, both in the xz and yz cross section images (Figure 4.8).

In order to better quantify internalisation of aggregated mutant SOD1 the mean
fluorescence intensity of individual cells was calculated. Astrocyte cultures treated with
aggregated SOD1G93A showed significantly greater mean fluorescence intensity
compared to astrocytes treated with PBS (Figure 4.9). While the amount of
fluorescence varied substantially in the aggregate treated cultures, the background
fluorescence in PBS treated samples showed little variation. This observation is
consistent with i) astrocytes taking up variable amounts of aggregated SOD1 and ii)
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with the fact that not all astrocytes took up the aggregated material. To confirm
internalisation western blot analysis on primary astrocyte cell lysates, previously
treated with aggregated biotinylated SOD1G93A, was carried out. Western blots showed
a smear greater than 150 kDa and some large aggregate trapped in the stacking gel
(Figure 4.10) in treated but not control lysates. When quantified, the density of the
band in the aggregate samples was found to be significantly greater than the control
sample (Figure 4.10). Some endogenous biotin signal can be observed in the control
sample and the aggregated biotinylated SOD1G93A sample at 120 kDa and was
considered background biotinylated protein (Figure 4.10) (Tytgat et al. 2015).

Figure 4.4: Statistics of scanning confocal micrographs determining purity of
cultures by staining for microglia. Primary cultures were then permeabilised
before probing for the microglial marker Iba-1 using a rabbit Iba-1 antibody (1:250)
and a secondary anti rabbit Alexa 647 (1:250). Less than 5% of cells have Iba1
staining in purified astrocyte cultures compared to 50-85% staining in mixed primary
cultures.

101 | P a g e

Primary
astrocytes

Microglia

Figure 4.5: Scanning confocal micrographs determining purity of cultures by
staining for microglia. Primary astrocytes and EOC.13 microglia were fixed then
permeabilised before probing for the microglial marker Iba-1 using a rabbit Iba1antibody (1:250) and a secondary anti rabbit Alexa 647 (1:250)

Aggregated SOD1 G93A

PBS

Figure 4.6: Scanning confocal micrographs of primary astrocyte internalisation
of aggregated SOD1 G93A. Cells were incubated with 40 μg/mL of aggregated
SOD1G93A for 2 hours at 37°C. After 2 hours, cells were fixed and permeabilised before
probing for Aggregated SOD1G93A (SA-Alexa 488) as indicated in green and glial
fibrillary acidic protein (Anti- rabbit Alexa 633) staining indicated by the red colour.
White dotted lines represent cell boundary as determined by transmission images.
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Figure 4.7: Statistics of scanning confocal micrographs to determine the level
of GFAP fluorescence between treatments. Aggregated SOD1G93A, H2O2 or PBS,
was added to primary astrocytes for 72 hours at 37C in a CO2 incubator. Astrocytes
cells were then permeabilised before probing for the astrocyte marker GFAP using a
rabbit GFAP antibody (1:250) and a secondary anti rabbit Alexa 647 (1:250). Results
are mean fluorescence (AU) ± standard error. * denotes significant difference.

Figure 4.8: Cross section of primary astrocytes showing the internalisation of
aggregated SOD1. The astrocytes were incubated with aggregated SOD1 G93A with a
biotin label for 2 hours at 37°C. They were then fixed using PFA 4%. A solution of 5%
BSA in PBS was used to block non-specific binding of antibodies. To probe for the
biotinylated aggregated SA-Alexa 488 (1:500) was incubated with the cells. Confocal
z stack was used to obtain a cross section of primary astrocytes. Red dotted lines
represent cell boundary as determined by transmission images.
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Figure 4.9: Internalisation of biotinylated aggregated SOD1G93A by murine
primary astrocytes. The astrocytes were incubated with aggregated SOD1 G93A with
a biotin label for 2 hours at 37°C. They were then fixed using PFA 4%. To permeabilise
all cell membranes 0.5% triton X-100 in PBS was incubated with the cells for 20
minutes. A solution of 5% BSA in PBS was used to block non-specific binding of
antibodies. To probe for the biotinylated aggregated SOD1G93A, SA-Alexa 488 (1:500)
was incubated with the cells. Confocal microscopy and analysis using Image J was
used to obtain the average mean fluorescence intensity *** denotes significant
difference between aggregated SOD1G93A treatment and the negative control.
Agg PBS

*
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Figure 4.10: Western blot of cell lysates from primary astrocytes incubated in the
presence of SOD1G93A aggregates. Primary astrocytes were incubated with 40
μg/mL of biotinylated SOD1G93A for 30 minutes at 37°C. Cells were then removed using
trypsin and washed before being lysed on ice for 30 min in 0.1% SDS Tris NaCl lysis
buffer. Lysates were then analysed by western blot and biotinylated aggregated SOD1
G93A was detected using a streptavidin HRP. Actin was used as a loading control and
density was determined through image j analysis. Results are means ± standard error
of triplicates and representative of at least two independent experiments. *Denotes
statistically significant increase when compared with the negative control (PBS) (P <
0.01). Arrow indicates background endogenous biotin signal in cultures.
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4.3.2 Clatherin independent macropinocytosis of aggregated SOD1G93A in
primary astrocytes
To further characterise the internalisation of aggregated SOD1G93A into primary
astrocytes a small panel of inhibitors of endocytosis were used. Primary astrocytes
were incubated with either Gen, MβCD, CPZ or EIPA which are inhibitors of caveolae
mediated endocytosis, lipid raft formation, clatherin mediated endocytosis and
macropinocytosis respectively (Zeineddine et al. 2015). There was no significant
difference between aggregate internalisation when incubated alone or in the presence
of MβCD, Gen or CPZ (Figure 4.11). However, internalisation of aggregated SOD1G93A
into primary astrocytes was significantly inhibited by incubation with EIPA P<0.001
(Figure 4.11). However, inhibition of uptake with EIPA did not totally block SOD1
interaction with the cells surface. In primary astrocytes treated with EIPA aggregated
SOD1G93A can be seen on the cell surface but it is not internalised (Figure 4.12).
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Figure 4.11: Inhibition of aggregated SOD1G93A clatherin independent
macropinocytosis in primary astrocytes. Primary astrocytes were isolated from
murine mixed glial cultures, before being treated with inhibitors (CPZ, EIPA, Gen and
MβCD) and then incubated with 40 μg/mL biotinylated aggregated SOD1G93A to
investigate internalisation. Cells were fixed and permeabilised before probing for
Aggregated SOD1G93A (SA-Alexa 488). Results are means ± standard error of
triplicates and representative of at least two independent experiments. *Denotes
statistically significant increase when compared with wild type SOD1-treated cells (P <
0.001).
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Figure 4.12: Cross section of primary astrocytes treated with inhibitors of
endocytosis and incubated with aggregated SOD1G93A. Astrocyte cultures were
incubated with inhibitors of endocytosis (EIPA, MβCD, CPZ, Gen or PBS for Agg
positive control) for 30 minutes before the addition of aggregated SOD1G93A with a
biotin label and a further 1 hour incubation at 37°C. They were then fixed using PFA
4%. A solution of 5% BSA in PBS was used to block unspecific binding of antibodies.
To probe for the biotinylated aggregated SA-Alexa 488 (1:500) was used. Confocal z
stack was used to obtain a cross section of primary astrocytes.

4.3.3 Cytokine release
Given the association of astrogliosis with ALS (Sekizawa et al. 1998, Rentzos et al.
2010a, Rentzos et al. 2010b) and our observation that astrocytes can take up SOD1
aggregates resulting in small increases in GFAP, we next looked to see if SOD1
aggregates would induce cytokine release associated with ALS. IL-6 and MCP-1 are
two immunologically important indicators of astrocyte activation and also important
ALS inflammatory mediators (Sekizawa et al. 1998, Nagata et al. 2007). To examine
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the effect of exogenous aggregated SOD1 on astrocyte activation, IL-6 and MCP-1
levels were examined using commercial ELISA kits. In the presence of aggregated
SOD1, primary astrocyte secretion of IL-6 and MCP-1 did not significantly increase
above basal levels after 72 hours (Figure 4.13).

Figure 4.13: Aggregated SOD1 does not cause IL-6 or MCP-1 cytokine release
when incubated with primary murine astrocytes. Aggregated SOD1G93A and PBS
(as a negative control) were incubated with the cells for 2 hours at 37°C. Media was
then replaced and cells incubated in a CO2 incubator at 37°C for 72 hours. MCP-1 and
IL-6 release was measured using a company ELISA kit with commercial standards
(ebiosciences, USA). No significant difference (NS).

4.3.4 Accumulation over time and cellular localization of aggregated SOD1G93A
To determine the fate of aggregated SOD1G93A internalised by astrocytes a time
course assay was used and SOD1 aggregated associated fluorescence was analysed
via confocal microscopy. Aggregated SOD1G93A was shown to remain within primary
astrocytes for up to 168 hours after aggregates were first added, without apparent
significant reduction in fluorescence or average size of the particle (Figure 4.14). To
examine where aggregated SOD1G93A was located within primary astrocytes a
selective

permeabilisation

experiment

was

performed.

While

triton X-100
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permeabilises all cellular membranes digitonin only permeabilises the outer cell
membrane (Nizard et al. 2007). While triton X-100 would allow the detection of SOD1
aggregates in the cytosol and within membrane bound compartments such as
endosomes or lysosomes, digitonin will only permeabilise the plasma membrane
allowing detection of SOD1 aggregates, using SA-Alexa 488 in the cytosol. Given that
fluorescent particles were observed after digitonin permeabilisation in addition to those
cells treated with triton X-100, we conclude that aggregated SOD1G93A can be found
present in the cytosol of primary astrocytes after uptake (Figure 4.15).
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Figure 4.14: Uptake of aggregated SOD1G93A overtime. The astrocytes were
incubated with aggregated SOD1G93A with a biotin label for 2 hours at 37°C. Media
was then replaced and cells incubated in a CO2 incubator at 37°C for a total of 24, 48,
72, 96, 120, 144 and 168 hours. They were then fixed using PFA 4% for 20 minutes
at room temperature. To permeabilise all cell membranes 0.5% triton X-100 in PBS
was incubated with the cells for 30 minutes at 4°C. A solution of 5% BSA in PBS was
used to block non-specific binding. To probe for the biotinylated aggregated SOD1G93A,
SA-Alexa 488 (1:500) was incubated with the cells for 60 minutes at 4°C.
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Figure 4.15: Aggregated SOD1G93A is present in the cytosol of primary astrocytes.
The astrocytes were incubated with aggregated SOD1G93A with a biotin label for 2
hours at 37°C. They were then fixed using PFA 4% for 20 minutes at room
temperature. To permeabilise all cell membranes, cells were incubated with 0.5%
triton X-100 in PBS for 30 minutes at 4°C. To selectively permeabilise the outer cell
membrane cells were treated with 10 μM digitonin in PBS for 10 minutes at 4°C. A
solution of 5% BSA in PBS was used to block non-specific binding of antibodies. To
probe for the biotinylated aggregated SOD1 cells were incubated with SA-Alexa 488
(1:500) for 60 minutes at 4°C.

4.3.5 Aggregated mutant SOD1 induces ER stress in primary astrocytes
Previous work has suggested that internalisation of SOD1 aggregates in to
neuroblastoma cells causes ER stress leading to cellular dysfunction and death
(Sundaramoorthy et al. 2013). To examine if internalisation of aggregated SOD1 leads
to ER stress in primary astrocytes, cells were transfected with the ER stress reporter
XBP1-venus. Treatment of primary astrocyte cultures with aggregated SOD1G93A lead
to a statistically significant increase in venus fluorescence, as did cells treated with a
known ER stress inducing agent thapsigargin, in comparison to the PBS only control
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(Figure 4.16). Addition of soluble SOD1G93A, soluble SOD1WT did not induce venus
expression above that of the PBS control (Figure 4.16), indicating soluble forms of
SOD1 do not induce ER stress. Another marker of UPR induced ER stress is the
increase in abundance of the ER Chaperone Bip (Oslowski and Urano 2011). Addition
of aggregated SOD1, but not soluble mutant or wild type SOD1, significantly increased
the levels of Bip when compared to the controls (Figure 4.17).

Figure 4.16: Aggregated SOD1G93A results in endoplasmic reticulum stress in
primary astrocytes. XBP-1 splicing (indicated here by green fluorescence) was used
to measure endoplasmic stress induced UPR. Aggregated SOD1G93A, soluble
SOD1G93A, soluble SOD1WT (and PBS as a negative control) was incubated with the
cells for 2 hours at 37°C. Media was then replaced and cells incubated in a CO 2
incubator at 37°C for 72 hours (protected from light). Cells were fixed with 4% PFA for
15 minutes at room and stored at 4°C for 24 hours before imaging on the confocal
microscope. *** Denotes statistically significant difference P<0.001.
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Figure 4.17: UPR induced Endoplasmic reticulum stress after treatment with
aggregated SOD1G93A. Western blot of cell lysates from primary astrocytes incubated
in the presence of 40 ug/mL SOD1G93A aggregates (Agg), soluble SOD1G93A (G93A)
and soluble wild type SOD1 (WT) for 72 hours (thapsigargin (Thaps) used as a positive
control and PBS as a negative control). Blots were probed for the ER stress marker
binding immunoglobulin protein (BiP) and β-actin was used as a loading control. A)
Representative western blot for BiP (n= 6 replicates) and β-actin as a loading control.
B) Representative SDS PAGE gel (n= 6 replicates) showing whole cell lysates from
primary astrocyte treatments C) Results are means ± standard error of 6 replicates
and representative of at least two independent experiments with 6 separate western
blots performed with PBS band density across each western blot given the density of
1 which all other results were compared to in that western. Then all 6 were compared.
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Band density was normalised against PBS across the different western blots. *
Denotes statistically significant difference P<0.05.
4.3.6 Aggregated mutant SOD1 induces senescence in primary astrocytes
Astrocyte senescence has been shown to be accelerated in rat models for ALS and
other neurodegenerative diseases such as Parkinson’s and Alzheimer’s disease (Bhat
et al. 2012, Chinta et al. 2013, Das and Svendsen 2015). To determine if aggregates
of mutant SOD1 could induce senescence in primary astrocytes taken from neonatal
mice two methods were used. Initially, a novel antibody recognising a cell surface
antigen associated with senescent cells was used (N. Cashman, Patent pending)
(Figure 4.18). Only when primary astrocyte cultures were treated with aggregated
SOD1G93A, not soluble mutant or wildtype SOD1, was there an increase in staining,
consistent with aggregates inducing senescence. To confirm that the antibody was
detecting senescent cells, astrocyte cultures were treated with H2O2 to induce
senescence (Bitto et al. 2010). To corroborate these findings a commercially available
β-Galactosidase kit that detects senescence was used. Primary astrocytes were also
shown to exhibit increased levels of β-Galactosidase when treated with aggregated
SOD1G93A and H2O2 when compare to controls (Figure 4.19).
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Figure 4.18: Scanning confocal micrographs of AMF-1c-120 staining in primary
astrocytes treated with SOD1. A Aggregated SOD1G93A, soluble SOD1G93A, soluble
SOD1WT (50μM H2O2 as a positive control and PBS as a negative control) was
incubated with the cells for 2 hours at 37°C. Media was then replaced and cells
incubated in a CO2 incubator at 37°C for 72 hours. Cells were fixed before probing for
senescent cells using AMF-1c-120 a rabbit mAb (1:1000) and an anti-rabbit Alexa 488
ab (1:500) for 60 minutes at 4°C. B Confocal microscopy and analysis using image J
was used to obtain the average mean fluorescence intensity per cell. Results are
means ± standard error of triplicates and representative of at least two independent
experiments. * Denotes significant difference p<0.05.
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Figure 4.19: Activation of senescence in primary astrocytes treated with
aggregated SOD1. Aggregated SOD1G93A, soluble SOD1G93A, soluble SOD1WT
(50μM H2O2 as a positive control and PBS as a negative control) was incubated with
the cells for 2 hours at 37°C. Media was then replaced and cells incubated in a CO 2
incubator at 37°C for 72 hours. Cells were fixed and stained using a commercial βGalactosidase staining kit. A) Light microscope images of senescent astrocytes in
each treatment. B) The 96 well plate was incubated at 37°C for 24 hours before the
absorbance was read at 490 nm using a Spectra Max Plus 384 spectrophotometer.
Results are means ± standard error of triplicates and representative of at least two
independent experiments. * Denotes statistically significant difference p<0.05.
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4.3.7 Aggregated mutant SOD1 results in an increase in Cell death
Given that exogenously applied aggregates were toxic to motor neuron like NSC-34
cells (Sundaramoorthy et al. 2013), we next tested whether uptake of aggregates
affected astrocyte viability. Initially to determine if aggregated SOD1G93A and/or soluble
SOD1G93A was toxic to astrocytes a propidium iodide (Pi) cell death assay was
performed. After 72 hours the percentage cell death of astrocytes treated with
aggregated SOD1G93A was significantly greater than the negative control (Figure 4.20).
In contrast soluble mutant SOD1 did not increase Pi staining from controls (Figure
4.20).

Figure 4.20: An increase in the percentage of cell death after treatment with
aggregated SOD1G93A. Aggregated SOD1G93A, soluble SOD1G93A (ethanol used as
100% cell death and PBS as a negative control) was incubated with the primary
astrocytes for 2 hours at 37°C. Media was then replaced and cells incubated in a CO2
incubator at 37°C for 72 hours. Results are means ± standard error of triplicates and
representative of at least two independent experiments. * Denotes statistically
significant difference p<0.05.

Due to the increase in cell death after treatment with aggregated SOD1G93A we next
examined caspase activation to determine if cell death occurred via apoptosis. To do
this a fluorogenic caspase substrate was added to cells. Using confocal microscopy,
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we observed substantial Flica fluorescence for both the aggregated SOD1G93A and
soluble SOD1G93A treated astrocytes but no increase was detected for wildtype SOD1
(Figure 4.21).

Figure 4.21: Scanning confocal micrographs of activation of caspases 3 and 7 in
primary astrocytes treated with SOD1. Aggregated SOD1G93A, soluble SOD1G93A,
soluble SOD1WT (and PBS as a negative control) was incubated with the cells for 2
hours at 37°C. Media was then replaced and cells incubated in a CO 2 incubator at
37°C for 72 hours. Staining perform as per Image-iT Live Red Caspase Detection Kit
protocol (Invitrogen). Sytox green was used to stain nucleus (green) and Flica reagent
was used to detect caspase (seen in red). N=6 * Denotes statistically significant
difference.
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4.4 Discussion
There is mounting evidence from ALS patient studies (both most mortem tissue and
live in vivo imaging) that both protein aggregates and glia play an active role in ALS
disease pathogenesis (Pramatarova et al. 2001, Watanabe et al. 2001, Wang et al.
2002, Clement et al. 2003, Turner et al. 2004, Beers et al. 2006, Wang et al. 2008,
Johnson et al. 2009, Fushimi et al. 2011, Guo et al. 2011). However, there has been
very few studies that have tried to examine and link these two aspects of disease.
Recent studies have shown that SOD1 aggregates in motor neurons can escape the
intracellular environment during motor neuron death (Grad et al. 2014). Interaction
between aggregates and microglia has been established not only in ALS (Roberts et
al. 2013) but also in other neurodegenerative diseases, indicating that activation of
non-neuronal cells by protein aggregates may play a role in disease progression (Le
et al. 2001, Bamberger et al. 2003, Deane et al. 2003, Halle et al. 2008, Su et al. 2008,
Reed-Geaghan et al. 2009, Murgas et al. 2012, Kim et al. 2013).

Here we investigated the effect of aggregated mutant SOD1 on astrocyte dysfunction
and subsequent toxicity. We show for the first time, uptake of aggregated SOD1
causes astrocyte senescence and death. Uptake of aggregated mutant SOD1 can be
inhibited by EIPA suggesting that endocytosis of aggregated mutant SOD1 by
astrocytes occurs via clatherin independent macropinocytosis. We also showed for the
first time, that internalisation of pre-aggregated SOD1G93A caused ER stress resulting
in UPR induction in primary astrocytes. Aggregates were observed to be maintained
in the cytosol of astrocytes for prolonged periods of time. Given prolonged ER stress
is known to cause the activation of caspases and subsequent apoptotic cell death, the
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findings presented here are consistent with the idea that aggregates released from
dead or dying neurons, could play a role in astrocyte dysfunction in ALS.

While previous studies have shown that SOD1 aggregates can escape the intracellular
environment (Münch et al. 2011, Grad et al. 2014), in the current work, SOD1
aggregates were made from recombinant protein to allow us to study the effects of
protein aggregates in isolation from the extracellular milieu. In order to visualise
internalisation of the aggregated protein a biotin label was added to the aggregates to
allow detection with streptavidin conjugates. Aggregated SOD1G93A was found to
rapidly enter astrocytes within 2 hours. In contrast, after internalisation the aggregated
protein was shown to remain within cells for a least a week in astrocyte cultures. This
suggests that internalised aggregates of SOD1G93A persist for an extended period of
time and astrocytes are not able to readily clear them.

In a previous study aggregated mutant SOD1 was shown to interact with scavenger
receptors and be internalised in a lipid raft dependent manner in microglia (Roberts
et al. 2013). In contrast to microglia, aggregated SOD1 internalisation in primary
astrocytes was found occur via clatherin independent macropinocytosis. Entry via
macropinocytosis is exploited by a range of pathogens including protozoa, bacteria
and viruses (Lim and Gleeson 2011). Interestingly, consistent with our results,
infectious prion proteins (and prion like proteins) have also been shown to utilise
macropinocytosis to gain entry into CHO cells (a cell line derived from a Chinese
hamster’s ovary), N2a cells (neuroblastoma cell line), HeLa cells (human
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adenocarcinoma cell line) and NIH3T3 cells (mouse fibroblast cells) (Magzoub et al.
2006, Wadia et al. 2008, Forget et al. 2013). Aggregates of mutant SOD1 have also
been shown to activate micropinocytosis in neurons (Zeineddine et al. 2015).

The effect of internalised aggregated mutant SOD1 on astrocytes would at least
partly depend on its final location within the cell. The present study determined that
after internalisation aggregated SOD1G93A could be found in the cytosol. This is
consistent with the Alzheimer’s associated protein tau, which has been shown to
gain entry into cytoplasm of a neuronal precursor cell line and displace tubulin (Frost
et al. 2009). In a similar manner, the current study showed uptake of SOD1
aggregates and little overlap with GFAP suggesting displacement of cytoskeleton
elements. Previous work involving prion proteins showed that aggregated proteins in
the cytoplasm were able to perturb the cytosolic protein quality control pathway
(Chakrabarti et al. 2011). Further work is required to fully determine what the effect
of translocation of SOD1 aggregates into the cytosol has on cellular homeostasis.
However, due to previous evidence that showed aggregate uptake stimulated ER
stress in neuron-like NSC-34 cells (Sundaramoorthy et al. 2013), the present study
examined if SOD1 aggregates induced ER stress and subsequent UPR in primary
astrocytes.

Increased levels of ER stress markers (downstream products of the IRE1 ER stress
pathways) can be found in ALS patient and transgenic mutant SOD1 mice tissue (Atkin
et al. 2006, Atkin et al. 2008). Up regulation of the PERK pathway has recently been
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reported to occur selectively in motor neurons (Sun et al. 2015). Research has also
been able to show up regulation of PDI in microglia and in anterior horn astrocytes
from mutant SOD1 transgenic mice, indicating that ER stress may also affect glial cells
(Jaronen et al. 2013, Jaronen et al. 2014). These studies importantly suggest a link
between ALS and ER stress but the cause of ER stress remains unclear. In the current
study, addition of aggregated ALS linked mutant SOD1 caused increases in UPR
markers consistent with ER stress in isolated primary astrocytes. We were able to
utilise a XBP-1 plasmid that when spliced by IRE1 produces an in frame venus
fluorescent protein, to monitor activation of UPR. Only aggregated SOD1G93A and not
soluble forms of SOD1, induced UPR in treated primary astrocytes. In addition, the
increased levels of BiP presented here, also indicated ER stress in astrocytes treated
with aggregates. Consistent with our work, previously published experiments, instead
looking at neuronal cells, showed ER stress after addition of aggregated SOD1
(Sundaramoorthy et al. 2013). Sudaramoorthy’s (et al. 2013) study reveals how
aggregated SOD1 inhibits protein transport between ER-Golgi, causing Golgi
fragmentation and ER stress, leading to the eventual cell death observed. Although
the current study did not examine ER-Gogli transport, this will likely be an important
avenue to follow up in future studies.

The initial response of the cell when the endoplasmic reticulum encounters misfolded
proteins is to mount a protective response in an attempt to restore proteostasis
(Korennykh et al. 2009). However, if homeostasis is not restored, the cell can activate
a cell death signalling cascade due to prolonged activation of IRE1 and CHOP
(Szegezdi et al. 2006). ER stress induced apoptosis also activates calpain mediated
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caspase 12 activation (Nakagawa and Yuan 2000). Our study showed that aggregated
SOD1G93A, introduced to astrocytes in culture, lead to both the prolonged accumulation
of biotinylated aggregates, ER stress, and an increase in the activation of caspases
leading to an increase in cell death. While astrocytes are known to be dysfunctional
and dying the mode of cell death is unknown.

In addition to cell death pathways, astrocytes have also been shown to initiate cellular
senescence in response to various stresses (Bitto et al. 2010). The astrocyte
senescence induced after the addition of aggregated SOD1 is consistent with βgalactosidase staining of astrocytes seen in spinal cord sections from mutant SOD1
rats (Das and Svendsen 2015). It is also consistent with growing evidence of astrocyte
senescence observed in other neurodegenerative diseases including Parkinson’s and
Alzheimer’s disease (Bhat et al. 2012, Chinta et al. 2013).

The increase in GFAP (reactive astrocyte phenotype) is also consistent with other
studies looking at ALS and aging astrocytes in vitro (Díaz-Amarilla et al. 2011, Kohama
et al. 1995, Morgan et al. 1997). The results presented here suggest that the
senescent phenotype represents subpopulations of astrocytes in the cultures treated
with aggregates. This increase in both senescence and GFAP has also been noted in
end stage mutant SOD1G93A mice (Das and Svendsen 2015).
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This is not the first time ER stress and senescence has been linked. This link has been
found in an Ataxia telangiectasia disease model (another disease of the central
nervous system that affects movement) (Liu et al. 2005). Our results overall are
consistent with this previous research, with astrocyte cells showing markers of ER
stress, with increased senescence and cell death. However, most experiments
presented in this chapter were carried out after 72 hours incubation. It will therefore
be important to determine whether or not senescence occurs prior to cell death in this
experimental paradigm.

Previous work demonstrates the importance of non-neuronal cells in the pathogenesis
of ALS (Alexianu et al., 2001; Hall et al., 1998; Henkel et al., 2006). Current thought is
that there are fundamental differences underlying disease initiation and disease
progression in ALS. This line of thought is based on results showing that mutant SOD1
was important in neurons for disease initiation and in glia for disease progression in a
mouse model of ALS (Boillee et al., 2006). Although the role of protein aggregation in
disease pathology has not been clarified, cells with SOD1 aggregates are more likely
to undergo cell death in culture models (Matsumoto et al., 2005; Soo et al., 2009). The
work presented here links these two observations and suggests that astrocytes that
have taken up SOD1 aggregates experience ER stress, become senescent, and may
undergo cell death, which would results in reduced trophic support for motor neurons
(Figure 4.22). As a result, blocking SOD1 aggregates from causing astrocyte
dysfunction may be effective in slowing ALS progression.
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Figure 4.22: Proposed pathway of aggregated SOD1 induced astrocyte
dysfunction and cell death. Neuronal cell death is associated with protein
aggregation. Upon cell death or dysfunction, aggregates can be released and taken
up by nearby astrocytes. SOD1 aggregates are taken up by astrocytes results in ER
stress, senescence and cell death, potentially leading to reduced trophic support of
motor neurons. A reduction in trophic support may leave motor neurons vulnerable to
further protein aggregation and cell death and subsequent release of aggregates in a
toxic feedback loop.
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5. Aggregated mutant
SOD1 activates microglia
and induces astrocyte
senescence when
injected into the brains of
mice
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5.1 Introduction
Increasingly,

the

importance

of

aggregates

and

non-neuronal

cells

in

neurodegenerative is being recognised and studied. There is growing evidence that in
the presence of extracellular deposits or plaques there is a direct interaction between
microglia and aggregated proteins resulting in activation (Mattiace et al. 1990). Aβ1-42
oligomers obtained from post-mortem tissue at low concentrations (5-50 nM) were
demonstrated to activate microglia in a similar fashion to their in vitro-formed
counterparts (Maezawa et al. 2011). Nitric Oxide was released from the microglial cells
but an observed absence of many of the pro-inflammatory factors that are often
associated with microglial activation, such as PGE2, TNF-α, IL-6 and IL-1β was noted.
In AD post mortem brain tissue and in AD mouse models, activated microglia also
accumulate in the areas of the brain harbouring impaired neurons and astrocytes
(Busche et al. 2008, Kuchibhotla et al. 2009) and are found surrounding plaques
(McGeer et al. 1987, Mattiace et al. 1990, Meyer-Luehmann et al. 2008).

Post-mortem brains of patients previously diagnosed with Parkinson’s disease, show
the highest loss of dopaminergic neurons in the substantia nigra pars compacta
(Agid 1991, Henry et al. 2009) an area which has previously been reported to have
the highest density of microglial cells in the brain (Lawson et al. 1990). In
Parkinson’s disease, activated microglia have been reported in brain tissue,
surrounding dopaminergic neurons (McGeer and McGeer 2008, Nakadate and
Tanaka-Nakadate 2015). When mice had α-synuclein aggregates injected into their
brains, microglia were observed to take up the aggregates and become activated
(Boza-Serrano et al. 2014).
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A number of studies have now shown that microglia are activated and proliferate in
ALS patients and ALS mice models (Lampson et al. 1988, Kawamata et al. 1992,
Henkel et al. 2004, Turner et al. 2004, Moisse and Strong 2006). As the disease
increases in severity, the activation of microglia has also been shown to increase
(Turner et al. 2004, Henkel et al. 2009) . Microglial activation is seen in mutant SOD1
transgenic mice before symptoms appear and throughout disease progression (Hall
et al. 1998, Alexianu et al. 2001, Clement et al. 2003). Immunocytochemistry of
postmortem tissue from ALS patients demonstrated microglial activation and indicated
that an immune response may play a role in motor neuron death (Troost et al. 1993).
Positron emission tomography imaging of living ALS patients, using [11C](R)-PK11195
and [11C]-PBR28 (with both radiotracers shown to bind specifically to activated
microglia), showed an increase in activated microglia in the motor cortex, that
correlates with upper motor neuron symptoms seen in patients (Banati 2002, Turner
et al. 2004, Zürcher et al. 2015). This data is consistent with microglial activation
playing an important role in disease progression.

A significant increase in astrocytic activation is seen in mutant SOD1 mice upon
disease onset and throughout the early stages of disease progression (Hall et al.
1998). It has also been revealed that astrocytes from neonatal rat spinal cords,
become reactive after incubation with CSF from ALS patients (Shahani et al. 1998).
While culture studies show lowering SOD1 expression in astrocytes lowers their
toxicity to motor neurons, diminished mutant SOD1 expression in astrocytes did not
affect disease onset but delayed microglial activation and slowed disease progression
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(Yamanaka et al. 2008). This evidence suggests that a complex relationship could be
occurring between SOD1, astrocytes and microglia in ALS to affect motor neurons.

There is increasing evidence that the misfolding of mutant SOD1 underlies disease
pathology (Wang et al. 2002). However, the precise mechanism by which SOD1
mutants are toxic remains unclear. There are a number of mutations in SOD1 that
have been shown to cause destabilisation of the structure of the protein, resulting in
the mutant forms of SOD1 having a greater propensity to aggregate (Borchelt et al.
1994). Although there is substantial evidence of both SOD1 aggregates and activation
of glial cells in patient pathology, very little research has focused on how SOD1
aggregates affect astrocytes and microglia when introduced directly in vivo.

As astrocytes and microglia have been shown to play a role in ALS we aimed to
determine if extracellular mutant SOD1 directly affected these cells when injected into
the brain of wild type mice (wild type mice were used to reduce confounding effects of
glial activation already existing in SOD1 transgenics). We found that while soluble WT
or mutant infused in to the lateral ventricle of mice had no effect on glial staining even
after 5 weeks of infusion, single injections of aggregated SOD1 resulted in robust
changes in glia in the brain. Importantly, we find that this in vivo data supported the in
vitro results of increased microglial activity and astrocyte senescence after the addition
of aggregated SOD1G93A.
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5.2 Methods

5.2.1 Animal housing and monitoring
Mice were ordered from Animal Resource Centre and housed in the University of
Wollongong animal facility for 1 week for acclimatization (AESOP0OI; AESOP002).
After surgery mice were housed individually to avoid over grooming or chewing of
implants from other mice.

Mice were monitored daily to check for any signs of distress from the surgery.
Monitoring examined posture, activity, eating/drinking, gait, respiration, hydration,
coat condition, grooming and surgical wound appearance.

5.2.2 Brain surgery for soluble infusions using an Alzet pump
Recombinant SOD1 was purified as previously outlined and LPS depleted using an
LPS removal column (Chapter 2). It was determined that aggregated forms of SOD1
would clog the tubing in the Alzet pumps and was therefore injected in a subsequent
experiment (see below). The protein was then infused over 5 weeks into the ventricle
of the mice, while weight and motor function was monitored (kindly performed by Dr
Brad Turner).

A scalpel was used to open the skin at the top of the skull, to allow ease of access
and to minimise gluing of the skin to the skull. The location of the catheter and pump
was calculated to bregma using the mouse/rat brain atlas (Paxinos G 2001). A drill
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(Foredom, USA) designed for mouse surgery was used to drill a hole into the skull.
The pump catheter was lowered into the brain before being raised 2 mm to allow the
application of glue around the base of the Alzet pump (Dureck, US). The incision was
sutured and a subcutaneous injection of an anti-inflammatory Meloxicam (APEX
laboratories, Australia) was injected. A stock solution of the analgesic Metacam was
made up at 100 μg/mL and the amount of Metacam used was determined for each
mouse. In this treatment 8 wild type and 8 transgenic 60 day old mice were used.
PBS, SOD1WT and SOD1G93A were added to the alzet pumps at 3.2 mg/mL and 250
μL was infused over 42 days. Therefore, the pumps infused at 0.15 μL/hour, with the
endpoint being when mice were ~100 days old. An overview/timeline of this procedure
can be seen in Table 5.2. Note however, that a number of PBS treated mice had to
be euthanized for ethical reasons after 90 days and tissue was not collected. This
meant that not enough replicates of the PBS control were available to do any
meaningful statistical analysis. Given that infusion of the soluble wild type SOD1 was
shown in previous experiments to have neuroprotective effects the experiment was
continued and any effect of SOD1G93A was judged on differences from SOD1WT
treatment.

5.2.3 Intracranial guide cannula surgery
For a more detailed methodology see previously published method (Engel et al. 2015).
Briefly, the correct location for the guide cannula was calculated to bregma using the
mouse/rat brain atlas (Paxinos G 2001). A drill (Foredom, USA) designed for mouse
surgery was used to drill a hole into the skull. Three more shallow holes, which were
used to secure the cannula, were drilled part way into the skull but not all the way
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through. A fine needle was then used to pierce through the delicate meningeal
membranes before the guide cannula was inserted. It was then secured using the
screws and the first layer of super glue. It was then further secured using dental
cement and another layer of super glue. A dummy cannula to prevent entry of foreign
debris was inserted and the mouse was removed from the stereotaxic device. The
surgical area was treated with betadine (an antiseptic solution) and a subcutaneous
injection of an anti-inflammatory Meloxicam (APEX laboratories, Australia) was given.
A stock solution of the analgesic Metacam was made up at 100 μg/mL and 100 μL
was introduced into mice using an intraperitoneal injection.

The animals were then monitored for any adverse signs to the surgery before being
left to recover. For 1 week post-surgery mice were monitored daily as previously
described.

Mice were allowed to recover from day 2 to 6. On day 7, 2 μL the recombinant protein
aggregates (100 μg/mL) or PBS (vehicle control) were injected into the brains of mice
using a small volume μL syringe. The dummy cannula was replaced after injections
and mice monitored as previously described for 72 hours. An overview/timeline of this
procedure can be seen in Table 5.1.
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Figure 5.1: Diagram showing positioning of intracranial guide cannula on the
mice used is this study.
5.2.4 Tissue collection
Mice were humanely sacrificed using a slow-fill CO2 inhalation technique to avoid
unnecessary suffering (see AESOP008) and they were rapidly perfused transcardially
with 0.9% saline and in some cases followed by ice-cold PBS- buffered 4% PFA, pH
7.4. Brains and spinal cords were rapidly removed from the animals for
immunohistochemistry or biochemical analysis. For experiments where aggregates of
SOD1 were injected into the ventricle, only brains were collected and analysed as
aggregates are not diffusible structures. Spinal cords were analysed in the soluble
SOD1 infusion experiments as it had previously been shown using SOD1 WT that
protein infused in to the ventricle reached the spinal cord in this time frame (Turner et
al. 2005).
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Table 5.1: Summary of injection of SOD1G93A aggregates into wildtype
mice over a 5 week period.

Week 1

Acclimatization

Week 2

Intracranial guide cannula surgery and monitoring of mice

Week 3

Study
Injection of protein and monitoring of mice

Week 3-5

Tissue collected
Tissue sectioning
Tissue Staining
Confocal imaging

Table 5.2: Summary of infusion of soluble SOD1WT and soluble SOD1G93A
protein into wild type mice over a 13 week period.

Week 1

Acclimatization

Week 2

Alzet pump surgery and monitoring of mice

Week 3+9

Infusion of protein and monitoring of mice

Week 10-13

Tissue collected
Tissue sectioning
Tissue Staining
Confocal imaging
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5.2.4 Immunological analysis of brain sections
Due to injection of SOD1 aggregates into the ventricle of the mouse brain lateral
sections examined were limited to the area of the brain surrounding the ventricle
(Figure 5.2). Brains from mice were sectioned via a Leica cryostat at 20 μm per section
and placed onto slides. Tissue sections were then thawed and a PAP pen was used
to draw a hydrophobic barrier around the brain sections to contain solutions added to
brain slices. A solution of 4% PFA in PBS was added to brain sections at room
temperature for 15 minutes. The samples were then wash 3 times with PBS between
each of the following steps. A permeabilisation solution (0.001% DMSO, 0.01% triton
X-100, 0.02% BSA made up in PBS), followed by a 5% BSA was used in a blocking
step. The primary antibodies; rabbit anti-Iba1 (1:250) (Wako, USA) used to identify
microglia, rabbit anti GFAP (1:250) used to stain for astrocytes; AMF-1c-120 a rabbit
mAb (Courtesy of Neil Cashman) (1:250) was used to probe for senescent cells, were
incubated with the brain sections overnight in a humidified chamber at 4°C. Secondary
detection antibodies; goat anti rabbit IgG Alexa 647 (1:250), was incubated for 1 hour
after washing with PBS. Cover slips were added to slides using Mounting media
(Prosci Tech, Australia) and CoverGrip coverslip sealant (Biotium, USA) was used
before slides were stored at -20°C. Slides were imaged on the Leica TCS SP5
confocal microscope (Leica, Germany) using imaging software LAS AF.

To minimise tissue injury that may conceal aggregated dependant gliosis (due to
gliosis caused by tissue injury from needle insertion) aggregates were injected into the
ventricles. Due to the location of PBS and aggregated mutant SOD1 injections (and
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the shorter 72 hour time frame before collection not allowing for anticipated infusion
throughout the CNS as was the case with the Alzet pump experiments), the area
around the ventricles were targeted for imaging using a tile scan and Z stack process.

Figure 5.2: Examples of the ventricle area targeted in the brains of mice
injected with aggregated SOD1 (Paxinos G, 2001).
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5.3 Results
5.3.1 Infusion of SOD1G93A does not increase microglial activity when
compared to SOD1WT infusion
Previous studies showed that Alzet pump infusion of recombinant wild type SOD1
efficiently reached spinal cord neurons and provided some benefit to the G93A rat
model of ALS (Turner et al. 2005). In vitro studies have shown that soluble
recombinant mutant SOD1 can activate microglia (Roberts et al. 2013). Here we
extended this work by infusing wild type and mutant SOD1 in to the lateral ventricle of
mice to determine if soluble mutant SOD1 would activate microglia in spinal motor
neurons (Roberts et al. 2013). Microglial activity in the anterior horn was examined
after a 5 week infusion with SOD1WT and SOD1G93A by staining for Iba-1 as used
previously (Ahmed et al. 2007). Given Iba-1 is present on resting microglia it can be
observed in both SOD1WT infused mice spinal cord tissue and in SOD1G93A infused
mice spinal cord tissue (Figure 5.3). However, when the level of Iba-1 staining was
quantified there was no significant difference between samples taken from mice
infused with SOD1G93A and mice infused with SOD1WT (Figure 5.4).

Microglia morphology in the anterior horn after infusion with SOD1WT or SOD1G93A was
also examined. Microglia (indicated by blue arrows) in the anterior horn of the spinal
cord sections previously treated with either SOD1WT or SOD1G93A, were shown to have
similar morphology (Figure 5.5).
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Figure 5.3: Scanning confocal micrographs of microglial activity in SOD1WT or
SOD1G93A treated murine spinal cord tissue. ALZET pumps containing SOD1Wt or
SOD1G93A were used to deliver treatments to wild type mice over a 5 week period and
the spinal cord tissue harvested. Tissue sections were cut to 30 μm sections using a
Leica cryostat. Tissue sections were then permeabilised before probing for the
microglial marker Iba-1 using a rabbit Iba-1 antibody (1:250) and a secondary anti
rabbit Alexa 647 (1:250). Images shown are representative of 18 images from 6
individual mice. The anterior horn is outlined and indicated by (AH). Scale bars in blue
are 50 μm.
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Figure 5.4: Quantification of scanning confocal micrographs of Iba-1 stained
microglia in SOD1G93A or SOD1WT treated murine spinal cord tissue. ALZET
pumps containing SOD1WT or SOD1G93A were used to deliver treatments to wild type
mice over a 5 week period. Tissue sections were cut to 30μm sections using a Leica
cryostat. Tissue sections were then permeabilised before probing for the microglial
marker Iba-1 using a rabbit Iba-1antibody (1:250) and a secondary anti rabbit Alexa
647 (1:250). Results are means ± standard error are representative of 6 individual
mice (3 mice infused with SOD1WT and 3 mice injected with SOD1G93A). Results were
not statistically significant different (NS).
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Figure 5.5: Black and white confocal micrographs of microglial morphology in
SOD1G93A and SOD1WT treated murine spinal cords. ALZET pumps containing
SOD1Wt or SOD1G93A were used to deliver treatments to wild type mice over a 5 week
period and the spinal cord tissue harvested. Tissue sections were cut to 30 μm
sections using a Leica cryostat. Tissue sections were then permeabilised before
probing for the microglial marker Iba-1 using a rabbit Iba-1 antibody (1:250) and a
secondary anti rabbit Alexa 647 (1:250). Images shown are representative of 18
images from 6 individual mice. The anterior horn is outlined in red and indicated by
(AH). Blue arrows point to microglia of interest.

5.3.2 Infusion of SOD1G93A does not does not result in increased Glial fibrillary
Acidic Protein when compared to SOD1WT infusion
An increase in GFAP, an astrocyte marker (Eng 1985), has previously been reported
in post-mortem spinal cord tissue from patients diagnosed with ALS (Fujita et al. 1998).
In addition, results from the previous chapter indicate that when added to astrocyte
cultures SOD1 protein aggregates stimulate a small but significant increase in GFAP
(Chapter 4). Therefore, the abundance of GFAP in the anterior horn (where the motor
neuron population is most prominent) was examined after a 5 week infusion with
SOD1WT and SOD1G93A. GFAP staining can be observed in both the SOD1G93A infused
mice spinal cord tissue and in SOD1WT infused mice spinal cord tissue (Figure 5.6).
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However, upon quantification there was no significant difference in the level of GFAP
staining between those samples taken from mice infused with SOD1G93A and those
from mice infused with SOD1WT (Figure 5.7).

AH

AH

AH

AH

AH
AH

Figure 5.6: Scanning confocal micrographs of GFAP stained astrocytes in
SOD1G93A or SOD1WT treated murine spinal cord tissue. ALZET pumps containing
SOD1WT or SOD1G93A were used to deliver treatments to wild type mice over a 5 week
period and the spinal cord tissue harvested. Tissue sections were cut to 30 μm
sections using a Leica cryostat. Tissue sections were then permeabilised before
probing for the astrocyte marker GFAP using a rabbit GFAP antibody (1:250) and a
secondary anti rabbit Alexa 647 (1:250). Images shown are representative of 18
images from 6 individual mice. The anterior horn is outlined and indicated by (AH).
Scale bars in blue are 50 μm.
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Figure 5.7: Quantification of scanning confocal micrographs of GFAP stained
astrocytes in SOD1G93A or SOD1WT treated murine spinal cord tissue. ALZET
pumps containing SOD1WT or SOD1G93A were used to deliver treatments to wild type
mice over a 5 week period. Tissue sections were cut to 30 μm sections using a Leica
cryostat. Tissue sections were then permeabilised before probing for astrocyte
senescence using AMF-1c-120 a rabbit mAb (1:250) and a secondary anti rabbit Alexa
647 (1:250). Results are means ± standard error are representative of 6 individual
mice (3 mice infused with SOD1WT and 3 mice injected with SOD1G93A). Results were
not statistically significant different (NS).

5.3.3 Infusion of SOD1G93A does not does not result in increased AMF-1c-120
staining when compared to SOD1WT infusion
The previous chapter demonstrated that the level AMF-1c-120 staining was consistent
with β-Galactosidase staining for senescence. AMF-1c-120 staining was therefore
examined in the anterior horn after a 5 week infusion with SOD1WT and SOD1G93A.
AMF-1c-120 is thought to recognise a cell surface antigen specific to senescent cells
(N. Cashman, Patent pending). AMF-1c-120 staining can be observed in both
SOD1G93A infused mice spinal cord tissue and in SOD1WT infused mice spinal cord
tissue (Figure 5.8). Quantification of AMF-1c-120 staining indicated that there was no
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significant difference in putative senescence staining between samples taken from
mice infused with SOD1G93A and mice infused with SOD1WT (Figure 5.9).
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Figure 5.8: Scanning confocal micrographs of astrocyte senescence in SOD1G93A
or SOD1WT treated murine spinal cord tissue. ALZET pumps containing SOD1WT
or SOD1G93A were used to deliver treatments to wild type mice over a 5 week period
and the spinal cord tissue harvested. Tissue sections were cut to 30μm sections using
a Leica cryostat. Tissue sections were then probed for astrocyte senescence using
AMF-1c-120 a rabbit mAb (1:250) and an anti-rabbit Alexa 647 ab (1:250). Images
shown are representative of 18 images from 6 individual mice. The anterior horn is
outlined and indicated by (AH). Scale bars in blue are 50 μm.
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Figure 5.9: Quantification of scanning confocal micrographs of astrocyte
senescence activity in SOD1G93A or SOD1WT treated murine spinal cord tissue.
ALZET pumps containing SOD1WT or SOD1G93A were used to deliver treatments to
wild type mice over a 5 week period. Tissue sections were cut to 30μm sections using
a Leica cryostat. Tissue sections were then probed for astrocyte senescence using
AMF-1c-120 a rabbit mAb (1:250) and a secondary anti rabbit Alexa 647 (1:250).
Results are means ± standard error are representative of 6 individual mice (3 mice
infused with SOD1WT and 3 mice injected with SOD1G93A). Results were not
statistically significant different (NS).

5.3.4 Infusion of SOD1G93A does not result in physical symptoms in mice
When determining deterioration of motor function and disease progression in mice,
body weight and latency to fall are commonly measured (Carter et al. 1999, Hayworth
and Gonzalez-Lima 2009). While these animals were not transgenic we nonetheless
tested for any signs of changes in wellbeing during the infusion protocol. There was
no significant difference over time within the group or between infusion of SOD1G93A
and SOD1WT treatments when measuring latency to fall (Figure 5.10). All mice
demonstrated a normal increase in weight as they grew older however there was no
significant difference in body weight between treatments (Figure 5.11) (kindly
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performed by Dr Bradley Turner). This data suggests that the infusion of both WT and
mutant forms of SOD1 are well tolerated in non-transgenic mice.

Figure 5.10: Motor function of mice after infusion of PBS, soluble SOD1WT or
soluble SOD1G93A. ALZET pumps containing PBS, SOD1WT or SOD1G93A were used
to deliver treatments to both wild type and SOD1G93A expressing mice over a 5 week
period. Latency to fall was used as an indicator of symptomatic mice (kindly
performed by Dr Bradley Turner).

Figure 5.11: Body weight of mice after infusion of PBS, soluble SOD1WT or
soluble SOD1G93A. ALZET pumps containing either PBS, SOD1WT or SOD1G93A
were used to deliver treatments to both wild type and SOD1G93A expressing mice
over a 5 week period. Body weight was used as an indicator of symptomatic mice
(kindly performed by Dr Bradley Turner).
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5.3.5 Injecting aggregated SOD1G93A results in increased microglial activity
Given that SOD1 aggregates are several fold more potent activators of microglia we
wanted to determine if these aggregates would activate microglia in vivo. Given that
the aggregates were not in solution and are were likely to block the tubing in Alzet
pumps a short-term single injection experiment was performed. Iba-1 staining around
the ventricles was examined after injection with aggregated SOD1 G93A compared with
control animals injected with PBS. Quantification revealed that there was a significant
increase (Figure 5.12) in iba-1 staining in mouse brains injected with aggregated
SOD1G93A (Figure 5.13) compared to those injected with PBS (Figure 5.14). Confocal
images show that the increase in the density of iba-1 staining (when compared to PBS
controls) is concentrated around the ventricles of aggregated SOD1G93A treated mice,
where there is an apparent increase in the density of Iba-1 staining when compared
to PBS control microglia (Figure 5.13 and 5.14). The significant increase in iba-1 could
also suggest an increase in the number of microglia although this could not be
accurately quantified (i.e. too difficult to distinguish individual cells amongst all the cell
processes).

Microglia morphology around the ventricles after injection with aggregated SOD1G93A
was also examined. In tissue surrounding the ventricles of PBS treatment samples,
microglia (indicated by blue arrows) have much smaller bodies with fine, hard to detect
processes. In the aggregated SOD1G93A treatment samples, microglia (indicated by
red arrows) have larger bodies with thick processes (Figure 5.15). The strong Iba-1
staining in the ependymal of aggregated SOD1G93A treatment samples is also striking
(Figure 5.15).
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Figure 5.12: Quantification of scanning confocal micrographs of microglial in
aggregated SOD1G93A or PBS treated murine brains. Mice were injected with
aggregated SOD1G93A or PBS, monitored for 72 hours and the brain tissue harvested.
Tissue sections were cut to 20 μm sections using a Leica cryostat. Tissue sections
were then permeabilised before probing for the microglial marker Iba-1 using a rabbit
Iba-1antibody (1:250) and a secondary anti rabbit Alexa 647 (1:250). Results are
means ± standard error of 72 individual images (see merged scanned images of
ventricles Figure 5.13 and 5.14) and representative of 6 individual mice (3 mice
injected with PBS and 3 mice injected with Aggregated SOD1G93A). * Denotes
statistically significant difference p<0.05.

147 | P a g e

Agg 1

Agg 2

Agg 3

Figure 5.13: Scanning confocal micrographs of Iba-1 stained microglia in
aggregated SOD1G93A treated murine brains. Mice were injected with aggregated
SOD1G93A, monitored for 72 hours and the brain tissue harvested. Tissue sections
were cut to 20 μm sections using a Leica cryostat. Tissue sections were then
permeabilised before probing for the microglial marker Iba-1 using a rabbit Iba-1
antibody (1:250) and a secondary anti rabbit Alexa 647 (1:250). The border between
brain and ventricle is outlined and the ventricle indicated by (V).
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Figure 5.14: Scanning confocal micrographs of Iba-1 stained microglia in PBS
treated murine brains. Mice were injected with PBS, monitored for 72 hours and the
brain tissue harvested. Tissue sections were cut to 20 μm sections using a Leica
cryostat. Tissue sections were then permeabilised before probing for the microglial
marker Iba-1 using a rabbit Iba-1 antibody (1:250) and a secondary anti rabbit Alexa
647 (1:250). The border between brain and ventricle is outlined and the ventricle
indicated by (V).
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Figure 5.15: Black and white confocal micrographs of microglial morphology in
aggregated SOD1G93A and PBS treated murine brains. Mice were injected with
aggregated SOD1G93A or PBS, monitored for 72 hours and the brain tissue harvested.
Tissue sections were cut to 20μm sections using a Leica cryostat. Tissue sections
were then permeabilised before probing for the microglial marker Iba-1 using a rabbit
Iba-1antibody (1:250) and a secondary anti rabbit Alexa 647 (1:250). The border
between brain and ventricle is outlined and the ventricle indicated by green dotted line.
Some microglia of interest are indicated by blue and red arrows.
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5.3.6 Injecting aggregated SOD1G93A does not result in increased Glial fibrillary
Acidic Protein Staining
Given the previously observed small increase in GFAP associated with adding SOD1
aggregates to astrocyte cultures, we sought to determine if introducing aggregated
SOD1 in to the brain of mice caused an increase in GFAP immunofluorescence. GFAP
staining was imaged and quantified after injection with aggregated SOD1. Both
aggregated SOD1G93A (Figure 5.16) and PBS (figure 5.17) treated sections showed
GFAP stained astrocytes surrounding the ventricles. However, there was no significant
difference in GFAP staining surrounding the ventricles of mice injected with
aggregated SOD1G93A and mice injected with PBS alone (Figure 5.18).
NS

Figure 5.16: Quantification of scanning confocal micrographs of GFAP stained
astrocytes in aggregated SOD1G93A or PBS treated murine brains. Mice were
injected with aggregated SOD1G93A or PBS, monitored for 72 hours and the brain
tissue harvested. Tissue sections were cut to 20μm sections using a Leica cryostat.
Tissue sections were then permeabilised before probing for the astrocyte marker
GFAP using a rabbit GFAP antibody (1:250) and a secondary anti rabbit Alexa 647
(1:250). Results are means ± standard error of 72 individual images (see merged
scanned images of ventricles Figure 5.17 and 5.18) and representative of 6 individual
mice (3 mice injected with PBS and 3 mice injected with Aggregated SOD1G93A). NS
denotes no significant difference.
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Figure 5.17: Scanning confocal micrographs of GFAP stained astrocytes in
aggregated SOD1G93A treated murine brains. Mice were injected with aggregated
SOD1G93A, monitored for 72 hours and the brain tissue harvested. Tissue sections
were cut to 20μm sections using a Leica cryostat. Tissue sections were then
permeabilised before probing for the astrocyte marker GFAP using a rabbit GFAP
antibody (1:250) and a secondary anti rabbit Alexa 647 (1:250). The border between
brain and ventricle is outlined and the ventricle indicated by (V). Scale bars in white
are 200 μm and scale bars in blue are 50 μm.
152 | P a g e

Figure 5.18: Scanning confocal micrographs of GFAP stained astrocytes in PBS
treated murine brains. Mice were injected with PBS, monitored for 72 hours and the
brain tissue harvested. Tissue sections were cut to 20μm sections using a Leica
cryostat. Tissue sections were then permeabilised before probing for the astrocyte
marker GFAP using a rabbit GFAP antibody (1:250) and a secondary anti rabbit Alexa
647 (1:250). The border between brain and ventricle is outlined and the ventricle
indicated by (V). Scale bars in white are 200 μm and scale bars in blue are 50 μm.
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5.3.7 Injecting aggregated SOD1G93A increases AMF-1c-120 staining
Transgenic rats with the human mutant SOD1 gene have previously been shown to
have an increased rate of astrocyte senescence (Das and Svendsen 2015). In
addition, an increase in markers of astrocyte senescence has also been found in postmortem tissue from patients diagnosed with Alzheimer’s disease (Bhat et al. 2012).
Therefore, we hoped to determine if aggregated protein, in this case SOD1, found in
patients with ALS, would cause astrocyte senescence in mice when introduced in vivo
using a novel antibody recognising a cell surface antigen specific to senescent cells
(N. Cashman, Patent pending).

A significant increase (Figure 5.19) in immunodetection using AMF-1c-120 was
observed in the brains of mice injected with aggregated SOD1G93A (Figure 5.20)
compared to those injected with PBS (Figure 5.21). The results in Chapter 4 are
consistent with the idea that this antibody detects changes that correspond to
astrocyte senescence, and in vivo after aggregate injection it strongly stains the
ependyma (consistent with GFAP staining) and the underlying white matter. This
suggests that aggregate treatment increases detection of astrocytes using AMF-1c120 suggesting astrocyte senescence in vivo. We also noted that there is apparent
intracellular staining of normal neurons using AMF-1c-120 outside of this region.
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Figure 5.19: Statistics of scanning confocal micrographs of astrocytes stained
for senescence marker (AMF-1c-120) in aggregated SOD1G93A or PBS treated
murine brains. Mice were injected with aggregated SOD1G93A or PBS, monitored for
72 hours and the brain tissue harvested. Tissue sections were cut to 20 μm sections
using a Leica cryostat. Tissue sections were then probed for astrocyte senescence
using AMF-1c-120 a rabbit mAb (1:250) and a secondary anti rabbit Alexa 647 (1:250).
Results are means ± standard error of 72 individual images (see merged scanned
images of ventricles Figure 5.20 and 5.21) and representative of 6 individual mice (3
mice injected with PBS and 3 mice injected with Aggregated SOD1 G93A). * Denotes
statistically significant difference P<0.05.
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Figure 5.20: Scanning confocal micrographs of astrocytes stained for
senescence marker (AMF-1c-120) in aggregated SOD1G93A treated murine
brains. Mice were injected with aggregated SOD1G93A, monitored for 72 hours and the
brain tissue harvested. Tissue sections were cut to 20 μm sections using a Leica
cryostat. Tissue sections were then probed for astrocyte senescence using AMF-1c120 a rabbit mAb (1:250) and an anti-rabbit Alexa 647 ab (1:250). The border between
brain and ventricle is outlined and the ventricle indicated by (V). Scale bars in white
are 200 μm and scale bars in blue are 50 μm.
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Figure 5.21: Scanning confocal micrographs of astrocytes stained for
senescence marker (AMF-1c-120) in PBS treated murine brains. Mice were
injected with PBS, monitored for 72 hours and the brain tissue harvested. Tissue
sections were cut to 20 μm sections using a Leica cryostat. Tissue sections were then
probed for astrocyte senescence using AMF-1c-120 a rabbit mAb (1:250) and an antirabbit Alexa 647 ab (1:250). The border between brain and ventricle is outlined and
the ventricle indicated by (V). Scale bars in white are 200 μm and scale bars in blue
are 50 μm.
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5.4 Discussion
There is growing evidence from patient studies that both protein aggregates and glia
have a role to play in ALS disease pathogenesis (Pramatarova et al. 2001, Watanabe
et al. 2001, Wang et al. 2002, Clement et al. 2003, Turner et al. 2004, Beers et al.
2006, Wang et al. 2008, Johnson et al. 2009, Fushimi et al. 2011, Guo et al. 2011).
However, there is a limited amount of in vivo evidence that examines and links these
two aspects of disease. Recent studies have shown that SOD1 aggregates in motor
neurons can escape the intracellular environment during motor neuron death providing
a rationale for glial-aggregate interaction (Grad et al. 2014). Interaction between
aggregates and glia has been established previously, not only in ALS (Roberts et al.
2013 and see Chapter 4), but also in other neurodegenerative diseases including
Alzheimer’s and Parkinson’s disease (Le et al. 2001, Bamberger et al. 2003, Deane
et al. 2003, Halle et al. 2008, Su et al. 2008, Reed-Geaghan et al. 2009, Murgas et al.
2012, Kim et al. 2013). In previous studies investigating other neurodegenerative
diseases, the respective protein aggregates (e.g. Aβ1-42 and α-synuclein aggregates)
have been injected into mice to discover the impact these aggregates had on glia
(Maezawa et al. 2011, Boza-Serrano et al. 2014). However, similar studies have not
previously been carried out to determine the effect introducing aggregated SOD1 has
on astrocytes and microglia. Here we investigated the effect of aggregated mutant
SOD1 on microglial activation and astrocyte function in vivo. We show for the first time,
while soluble forms of SOD1 have no effect of glial markers, microglia activation and
astrocyte dysfunction are significantly increased after exposure to aggregated mutant
SOD1.
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Aggregated SOD1G93A was previously shown to potently activate both EOC.13 cells
and primary microglia in vitro (Roberts et al. 2013). In the current study, we injected
aggregated SOD1G93A into the central nervous system of mice to examine the
response of microglia in vivo. Consistent with our previous in vitro work introducing
aggregated SOD1G93A increased microglia activity after just 72 hours exposure to the
aggregates. Interestingly, the microglial morphology in tissue from the aggregated
SOD1 treated brains was notably altered compared to the control brains. What has
previously been classified as ramified non-reactive microglia (Kettenmann et al. 2011,
Hook et al. 2015) (small bodies can be seen but the thin processes are difficult to see
here) were observed in the PBS control treated brains. However, microglia from the
brains of mice injected with aggregated SOD1 could be classified as hypertrophic
microglia (large bodies think stumpy processes) (Kettenmann et al. 2011, Hook et al.
2015). These results are consistent with another aggregation associated animal
model, in this case modelling Alzheimer’s disease (Stalder et al. 1999). In this study
they also found hypertrophic microglia in areas with dense amyloid plaques (Stalder
et al. 1999). Together, these results suggest that if aggregated SOD1 inclusions are
released from neurons in ALS patients, the interaction of aggregates and microglia will
result in their activation. Given the presence of microgliosis around degenerating
neurons in ALS it is likely that at least some of the activation previously observed in
vivo (Turner et al. 2004) is a result of glia-aggregate interactions.

While aggregated SOD1 added to primary astrocytes in culture resulted in small but
significant increases in GFAP, there was no significant increase in GFAP
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immunoreactivity in mice injected with aggregated SOD1. It is possible that this was
due to differences in the experimental models. In the cultures of primary astrocytes,
they are isolated from other cells, and the small effects seen in vitro that don’t translate
to the in vivo work may be due to factors (such as NO or other signals) produced by
astrocytes that will further activate other astrocytes in culture but that may be taken up
by microglia or other cells in the three dimensional setting of the mouse brain
(Brahmachari et al. 2006). In the complex environment of the brain there is a possible
interplay between astrocytes and other cells, indeed the affinity of different cell types
for aggregated SOD1 may mean that astrocytes receive a much lower dose compared
to the controlled dose applied to enriched astrocyte cultures in in vitro experiments.
There was also no significant difference in GFAP staining in spinal cords of mice
undergoing infusion of SOD1 over 5 weeks between mutant and wild type SOD1. This
suggests that an increase in GFAP is not induced by the soluble mutant form or the
aggregated form of the SOD1 protein. Previous work has reported an increase in
GFAP in the anterior horn of post mortem spinal cord tissue from patients diagnosed
with ALS (Fujita et al. 1998) the current work suggests that aggregates may not
contribute to this signal. However, more recent evidence suggests that loss of GFAP
could accelerate disease progression in a mutant SOD1 transgenic mouse model of
ALS (Yoshii et al. 2011), the work presented here is consistent with the idea that
uptake of aggregates from dead or dying neurons may contribute to astrocyte loss and
thus disease progression in ALS.

There

is

growing

evidence

of

astrocyte

senescence

observed

in

other

neurodegenerative diseases including Parkinson’s and Alzheimer’s disease (Bhat et
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al. 2012, Chinta et al. 2013). Here we show that aggregated SOD1 resulted in
increased staining with AMF-1c-120, which in Chapter 4 correlated to astrocyte
senescence. This is consistent with recently published results that showed βgalactosidase staining in spinal cord sections from mutant SOD1 rats (Das and
Svendsen 2015). It is also consistent with our previous results in primary culture using
the novel senescence antibody (N. Cashman, Patent pending) and β-galactosidase to
detect senescence after the addition of aggregated SOD1.

While aggregated SOD1 affected glia in short term experiments, infusion of soluble
forms of SOD1 did not. A statistical increase in microglial activity or astrocyte
senescence could not be measured in spinal cord samples from mice infusion with
SOD1G93A compared SOD1WT infused mice. This is inconsistent with work previously
performed in primary microglia which showed a small but significant increase in
microglial activity after the addition of soluble SOD1 G93A (Zhao et al. 2010, Roberts et
al. 2013). Microglia may be over activate in vitro and the small effects seen in vitro that
don’t translate to the in vivo work may be due to inhibitory factors produced by
astrocytes and neurons in mice brains (Neumann et al. 1998, Hoek et al. 2000, Chang
et al. 2001, Hailer et al. 2001). However, this lack of difference in both microglial
activity or astrocyte senescence between in vivo samples is consistent with the lack
of significant difference between treatments when measuring latency to fall and body
weight.
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Previous research has shown that mutant SOD1 was important in neurons for disease
initiation and in glia for disease progression in a mouse model of ALS (Boillee et al.,
2006). Although the role of protein aggregation in disease pathology has not been
clarified, SOD1 aggregates have been shown to be toxic to the neurons when they
accumulate in culture (Matsumoto et al., 2005; Soo et al., 2009). The results presented
here, in both the in vitro and in vivo studies (Chapters 3, 4 and 5), show for the first
time that introduction of aggregates of mutant SOD1 causes astrocyte senescence
and microglial activation. This work provides a potential link between SOD1
aggregates and microglial activation and astrocyte dysfunction, and thus provides
evidence that protein inclusions may also be linked to disease progression in a noncell autonomous manner apart from neuron to neuron transmission observed in other
studies (Grad et al. 2014, Ayers et al. 2016). As a result, in the future stopping SOD1
aggregates from causing microglial activation and astrocyte dysfunction may be
effective in slowing ALS progression.
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6. Conclusions and future
directions
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It

is

becoming

increasingly

acknowledged

that

protein

aggregates

and

neuroinflammation have an important role to play in many neurodegenerative diseases
(Hook et al. 2015). And although the presence of aggregates and neuroinflammation
has been well documented in ALS the direct effect of these aggregates on microglia
and astrocytes has not been closely examined in vitro or in vivo.

The specific aims of the study presented in this thesis were 1) to determine if ALS
associated mutant SOD1 aggregates activate primary murine microglia, 2) to
determine if ALS associated mutant SOD1 aggregates cause dysfunction in primary
murine astrocytes, and 3) to establish if extracellular aggregated mutant SOD1
mediates microglial activation and astrocyte dysfunction in vivo. These aims were
addressed in chapters 3, 4 and 5 respectively.

Microgliosis is now well documented in ALS, both in vitro and in transgenic mice
models and more importantly in vivo in ALS patients (Lampson et al. 1988, Kawamata
et al. 1992, Henkel et al. 2004, Turner et al. 2004, Moisse and Strong 2006). In ALS
models, microglia have previously been shown to exhibit neurotoxic phenotype
markers such as increased levels of TNF-α and IL-23 (Poloni et al. 2000, Rentzos et
al. 2010a). This neurotoxic microgliosis would put already stressed motor neurons
under increased strain and potentially contribute to ALS progression through the
release of neurotoxic factors and potentially toxic aggregates from microglia (Figure
6.1) (Appel et al. 2011). Protein inclusions made of SOD1 (and other proteins) in ALS
post mortem tissue has also been well-established and a propagation of protein
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aggregates and neuropathology has been proposed (Shibata et al. 1996, Forsberg et
al. 2011).

Figure 6.1: Representation of the possible role that aggregates play in ALS.
SOD1 aggregates are taken up by microglia causing microglia to switch to a neurotoxic
phenotype. SOD1 aggregates taken up by astrocytes causing astrocyte; ER stress,
senescence and cell death, potentially leading to reduced trophic support of motor
neurons, motor neuron cell death and release of aggregates. Aggregates represented
in black, neurotoxic microglia in green, senescent astrocytes in yellow and motor
neurons in blue.
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Therefore, as both protein inclusions and microgliosis are associated with ALS, the
first aim of this project sought to determine if aggregated SOD1 would activate
microglia. Recombinant SOD1 was aggregated and this, or soluble non-aggregated
forms of SOD1 were then added to EOC.13 microglial cells or primary microglial cells
in culture. Although soluble non-aggregated mutant SOD1 had been shown to promote
microglial activation in past studies (Zhao et al. 2010), we for the first time found that
aggregated SOD1 was able to much more efficiently activate microglia in culture when
compared with the unaggregated form of mutant SOD1. In addition to CD14
dependant pathways, we were able to show that aggregated SOD1 also bound to the
surface of glial cells and was internalized in a lipid raft and scavenger receptor
dependent manner. Identifying the precise mechanism by which aggregated SOD1
activates microglia to produce a neurotoxic phenotype is an important step in
understanding how microgliosis in ALS, results in increased stress to already stressed
and dying neurons (Figure 6.1).

Mutant Cu/Zn superoxide dismutase (SOD1) has previously been shown to reduce the
expression of glutamate transporter 1 in astrocytes, likely resulting ultimately, in
excitotoxicity for surrounding neurons (Ferraiuolo et al. 2011). Dysfunctional
astrocytes could also affect the uptake and release of lactate, ATP, glycine adenosine
and various growth factors (Figure 6.1) (Sofroniew and Vinters 2010). Like the
aforementioned microglia from post mortem tissue, the presence of aggregates is
similarly seen in astrocytes from ALS patients (Shibata et al. 1996, Kato et al. 2000,
Forsberg et al. 2011). As protein inclusions and astrocyte dysfunction are thought to
be an important part of ALS, the second aim of this project sought to determine if
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exogenous aggregated mutant SOD1 would induce astrocyte dysfunction in vitro.
Recombinant mutant SOD1G93A was aggregated and subsequently added to primary
astrocytes in culture. The results showed that exogenously added aggregated mutant
SOD1G93A is taken up into the cytosol of astrocytes, sustained for an extended period
of time, causing endoplasmic reticulum stress, astrocyte senescence and ultimately
cell death. This work, for the first time has shown that exogenously aggregated mutant
SOD1 causes dysfunction and toxicity in primary astrocytes. These results suggest
that there may be a potential link between protein aggregation and astrocytic
dysfunction in ALS.

The work presented here also showed, with the use of a panel of endocytosis
inhibitors, that aggregated SOD1 was internalized by primary astrocytes via
macropinocytosis. As mentioned previously with the mode of entry into microglia, the
mode of entry of aggregated SOD1 into astrocytes could also represent a target for
future drugs in the treatment of ALS. As microglia, astrocytes, motor neurons and
possibly other cell types are able to take up aggregates, the search for a treatment
based on cellular uptake might prove difficult. Although, one might imagine that
modulating aggregate uptake may be possible given that microglia use phagocytosis
and neurons/astrocytes use micropinocytosis. Given it is detrimental to both neurons
(Matsumoto et al. 2005) and astrocytes to take up SOD1 aggregates it might be
possible to divert aggregates to microglia by using micropinocytosis inhibitors.
However, this would potentially increase microgliosis so it would have to be delivered
in combination with a therapeutic strategy to alter the microglia phenotype from M1
towards M2.
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As microglia and astrocytes have been shown to play a key role in the healthy
functioning of the central nervous system, the third aim of this thesis was to gain a
better understanding of the impact that aggregated SOD1 and soluble SOD1 has on
microglia and astrocytes in vivo. Here we report that soluble SOD1G93A infused over 5
weeks into wild type mice, resulted in no significant impact on anterior horn microglia
and astrocytes, when compared to soluble SOD1WT infusion. Whereas, 72 hours after
injection aggregated SOD1 caused increased microglial activity and astrocyte
senescence surrounding ventricles. One might predict that infusion of aggregated
SOD1 over five weeks would more accurately simulate the prolonged progression
what occurs in transgenic mutant mice (and hence more closely simulate disease
progression in ALS patients). We would have liked to do a similar infusion of the
aggregated in this manner, however, this would have clogged the Alzet pumps and
therefore an alternative short-term experiment was performed with direct injections via
the intracranial guide cannula. This method was used to limit the local inflammation
due to injection as the implantation of the cannula allowed inflammatory markers time
to return to basal levels. In future experiments, a longer experiment examining the
effects of injected aggregated SOD1 through time would be vital to determine if
microglial activation persists and astrocyte function remains impaired.

Taken together with current literature, the data presented here suggest a model
(Figure 6.1) in which 1) neurons trigger ALS by accumulating SOD1 aggregates
(Matsumoto et al. 2005, Soo et al. 2009), 2) the dead or dying neurons release
aggregates which can be taken up by neurons, astrocytes or microglia ((Zeineddine
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et al. 2015), Chapter 3 and Chapter 4)), 3) these aggregates induce a neurotoxic
phenotype in microglia, and 4) cause senescence and death in astrocytes which may
result in a decrease in trophic support for neurons. The work presented here provides
evidence of the detrimental effect that the addition of SOD1 aggregates can have,
causing microglial activation and astrocyte dysfunction. As a result, future therapeutics
that prevents both SOD1 aggregate induced microglial activation and astrocyte
dysfunction may be effective in slowing ALS progression.
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Figure 8.1: A 15 % SDS-PAGE gel of fractions obtained from size exclusion
column. Gel was run at 120 V. Fractions of 2 mL were collected and every second
fraction eluted between 50-80 mL was analysed. Samples of SOD1 that had a purity
greater than 95% were then pooled and western blotting was performed to confirm
the presence of SOD1.
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Figure 8.2: Native mass spectrum of SOD1 wild-type. Briefly, purified SOD1 at a
concentration of 5 uM in 200 mM NH4OAc (pH 6.8) was nano-electrosprayed into a
SYNAPT G1 HDMS mass spectrometer. This figure is an expansion of the
dissociated 6+ charge state monomer under mild activation energy (40 V Trap). The
major species in this spectra is a peak with a mass of 15930 Da which corresponds
to a fully metalated SOD1 monomer. Other unlabeled peaks in this spectra
correspond to various oxidative modifications made to Cys111 during purification
(Mass spectrometry performed by Luke McAlary).
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